Ebook Pediatric critical care medicine (Volume 3: Gastroenterological, endocrine, renal, hematologic, oncologic and immune systems - 2nd edition): Part 2

Part IV
The Hematologic System in Critical Illness and Injury
Jacques Lacroix


Transfusion Medicine

19

Marisa Tucci, Jacques Lacroix, France Gauvin,
Baruch Toledano, and Nancy Robitaille

Abstract 

Anemia is common in pediatric intensive care units (PICU). Severe anemia can s­ ignificantly
increase the risk of death. Only a red blood cell (RBC) transfusion can rapidly treat a severe
anemia. In stable PICU patients, RBC transfusion is probably not required if the hemoglobin concentration is above 7 g/dL, unless the patient has a cyanotic cardiac condition. The
trigger or goal that should be used to direct RBC transfusion therapy in unstable critically
ill children remains undetermined, although some data suggest that RBC transfusion may
help in the early treatment of unstable patients with sepsis if their ScvO2 is below 70 % after
mechanical ventilation, fluid challenge, and inotropes/vasopressors perfusions have been
initiated. Plasma and platelets are used to prevent or to treat hemorrhage attributable to a
coagulopathy, thrombocytopenia or platelet dysfunction. The risks and benefits of plasma
and platelet concentrates in PICU patients are discussed. There is almost no evidence at the
present time that might permit a strong recommendation with regard to the use of plasma
and platelets in PICU. Good knowledge of transfusion reactions is required in order to
appropriately estimate the cost/benefit ratio of transfusion. Nowadays, non-infectious serious hazards of transfusion (NISHOT) are more frequent and more challenging for pediatric
intensivists than transfusion-transmitted infectious diseases. The decision to prescribe a
­transfusion must be tailored to individual needs and repeated clinical evaluation of each
critically ill child.
Keywords 

Anemia • Erythrocyte • Plasma • Platelets • Transfusion

M. Tucci, MD
Department of Pediatrics, Sainte-Justine Hospital,
University of Montreal, 3175 Cote Sainte-Catherine,
Montreal, QC H3T 1C5, Canada
e-mail:
J. Lacroix, MD (*)
Department of Pediatrics, Sainte-Justine Hospital
3175 Cote Sainte-Catherine, Montreal, QC H3T 1C5, Canada
e-mail:
F. Gauvin, MD, FRCPC, MSc • B. Toledano, MD, FRCPC, MSc
Division of Pediatric Critical Care Medicine,
Department of Pediatrics, Faculté de Médecine,
Sainte-Justine Hospital, Université de Montréal, Montreal, Canada
N. Robitaille, MD, FRCPC
Division of Hematology-Oncology, Department of Pediatrics,
Faculté de Médecine, Sainte-Justine Hospital,
Université de Montréal, Montreal, Canada
D.S. Wheeler et al. (eds.), Pediatric Critical Care Medicine,
DOI 10.1007/978-1-4471-6416-6_19, © Springer-Verlag London 2014

Transfusion of Red Blood Cells
Anemia in the PICU
Anemia—defined as a hemoglobin (Hb) concentration below
the “normal” range for age—has been reported to occur up to
74 % of critically ill children with a pediatric intensive care
unit (PICU) stay longer than 2 days. Indeed, anemia is
already present at the time of PICU admission in 33 % of

children, and an additional 41 % develop anemia during their
PICU stay [1]. Patients who become anemic gradually over a
long period of time and who are chronically anemic are more
tolerant of their anemic state than those who develop anemia
acutely. The main symptoms and signs of acute anemia are
259


260

not specific and include pallor, tachycardia, lethargy and
weakness. An increased blood lactate level and elevated oxygen (O2) extraction ratio (>40 %) can also be observed in
severe cases [2].
The etiology of anemia may be attributable to: (1) blood
loss, (2) decreased bone marrow production, which may in
part be secondary to a disturbed bone marrow response to
erythropoietin [3], (3) decreased RBC survival [4], and (4)
anemia due to underlying diseases such as cancer and congenital hemoglobinopathies. However, blood loss is the most
important cause of anemia acquired in the PICU. Blood
draws account for 70 % of all blood loss (0.32 mL/kg/day in
PICU), and procedures and hemorrhage are other causes of
blood loss [1].
In healthy animals undergoing acute hemodilution, evidence of heart dysfunction appears only once the Hb concentration drops below 3.3–4 g/dL [5, 6]. However, animals
with 50–80 % coronary artery stenosis can show evidence
of ischemic insult to the heart with a Hb concentration as
high as 7–10 g/dL [7]. In human beings, Carson et al. [8]
studied the outcome after surgery in 1,958 patients who
declined transfusion for religious reasons; the odds ratio for
death started to increase in those with prior ischemic heart
disease when their pre-operative Hb concentration

decreased below 10 g/dL. Carson et al. [9] also studied the
outcome after surgery in 300 patients without prior ischemic heart disease who declined transfusion for religious
reasons. The odds ratio for death started to increase when
the post-operative Hb concentration dropped below 4 g/dL.
There are some data describing the relationship between
anemia in severely ill children and mortality. A prospective
cohort study in Kenya of 1,269 hospitalized children with
malaria showed that RBC transfusions decreased death rate
if anemia was severe (Hb level < 4 g/dL) or if some dyspnea was associated with a Hb level < 5 g/dL [10]. In
another study conducted in Kenya, Lackritz et al. [11] followed 2,433 hospitalized children younger than 12 years
with chronic or acute anemia among which 20 % received
RBC transfusions. Some benefit was observed when a RBC
transfusion was given to patients with a Hb level below
4.7 g/dL, and if there were signs and symptoms of respiratory disease. Given these results, guidelines were written
suggesting that a RBC transfusion should be given to all
children with a Hb level < 5 g/dL hospitalized in this
Kenyan hospital. Subsequently, Lackritz et al. [12] undertook a prospective study in 1,223 consecutively hospitalized children. The Hb level was <5 g/dL in 303 patients. Of
these patients, 116 (38 %) did not receive a transfusion,
mostly because packed RBC units were not available. Each
of these 303 children with severe anemia was paired with
the next child hospitalized with a Hb level > 5 g/dL; none
of the latter children with a Hb level > 5 g/dL received a

M. Tucci et al.

RBC transfusion. Overall mortality was 30 % in the 303
children with a Hb level < 5 g/dL and 19.5 % in those with
a Hb level > 5 g/dL (p < 0.01). Among the 303 patients with
a Hb < 5 g/dL, mortality in transfused versus non transfused
children was respectively 21.4 % and 41.4 % (p < 0.001).

These studies suggest that there may be some benefit in
keeping the Hb concentration of hospitalized children
above 5 g/dL, though a higher threshold Hb concentration
may be required in critically ill children.
Severe anemia, as described in the studies above, results
in tissue hypoxia, which is likely the main mechanism leading to increased morbidity and mortality in these patients. Of
note, tissue hypoxia may be due not only to a low Hb concentration (anemic hypoxia), but also to abnormal blood flow
(stagnant hypoxia), decreased Hb saturation (hypoxic
hypoxia) or to mitochondrial dysfunction (cytotoxic or cytopathic hypoxia) [13]. Stagnant hypoxia can be caused by
dysregulated blood flow in the central circulation (cardiac
output), the regional circulation (distribution of blood flow
between organs), or the microcirculation (distribution of
blood flow within organs) [14–16].

 daptive Mechanisms to Acute Anemia
A
in Critically Ill Patients
While the risks of blood transfusion have been extensively
characterized, the risks of anemia are poorly understood,
especially in critically ill patients. Shander [7] described the
consequences of anemia in the critically ill patient and
explained the adaptive mechanisms involved. Anemia significantly decreases the O2 carrying capacity of blood. In the
normal host, the amount of O2 delivered (DO2) to tissue
exceeds resting O2 requirements by a factor of two to fourfold [13, 17]. When the Hb concentration falls below 10 g/
dL, several adaptive processes ensure a considerable physiologic reserve that maintains DO2 in spite of major adversity.
These adaptive processes include: (1) increased extraction of
available O2, (2) increased cardiac output (elevated heart rate
and stroke volume as well as decreased peripheral vascular
resistance and blood viscosity) [18], (3) redistribution of
blood flow from non-vital organs to the heart and brain, at

the expense of the splanchnic vascular bed, and (4) a right
shift of the oxyhemoglobin-dissociation curve (leading to
decreased O2 affinity and therefore increased O2 release) [13,
14, 18, 19]. All these mechanisms facilitate O2 unloading to
tissues. Severe anemia triggers additional adaptive mechanisms, which have limited compensation, such as an increase
in cellular O2 extraction. Indeed, this explains why there
exists a critical threshold of DO2 below which O2 consumption (VO2) begins to fall and selective vasoconstriction is
observed, which favors blood flow to critical organs, namely
the brain and heart, and deprives other organs, in particular
those irrigated by the splanchnic vascular bed [13].


19  Transfusion Medicine

I mpairment of Adaptive Mechanisms to Anemia
A number of diseases and host characteristics may impair
adaptive mechanisms to anemia in critically ill patients.
Cardiac compensation is limited when anemia is associated
with hypovolemia or cardiac dysfunction. Disease processes
such as sepsis and multiple organ dysfunction syndrome
(MODS) affect a number of adaptive mechanisms. In sepsis
and MODS there is often a high metabolic rate and increased
VO2 that substantially limit the available O2 reserve and may
result in a situation where demand is not met if an additional
metabolic stress occurs. In addition, these patients may also
have impaired left ventricular function [20, 21], and abnormal regulation of vascular tone [22, 23], restricting DO2 and
redistribution of blood flow, respectively. Moreover, sepsis
and MODS may compound the energy crisis observed in
many critically ill patients by causing mitochondrial oxidative dysfunction, decreasing tissue O2 extraction as well as
its utilization [14, 18]. Finally, decreased RBC deformability, which can alter microcirculatory function, is also

observed with sepsis and MODS.
A number of host characteristics specific to children and
infants may also impair their adaptive mechanisms. The
energy requirements of young infants are much higher than
those of adults [24]. This difference is mostly attributable to
growth and implies a greater need for substrates including O2
and nutrients. In addition to increased metabolic demands,
there are also major differences in O2 delivery between adults
and children in the first years of life. Fetal Hb represents a
greater proportion of total Hb during the first few months of
life, which can cause a left shift of the Hb saturation curve and
thus affect O2 delivery to tissues. Physiologic decrease in Hb
concentration is normal in newborns and partially explains the
great variability in normal Hb values seen during the first
weeks of life. During these weeks, myocardial compliance is
decreased, which causes significant impairment in diastolic
filling that can limit an increase in stroke volume when needed
to maintain O2 delivery. Moreover, the resting heart rate is
relatively elevated in newborns (140 ± 20/min) and in infants
(130 ± 20/min), which also limits their ability to increase cardiac output via increasing their heart rate. On the other hand,
the health status of children prior to PICU entry is usually better than that of adults, which might explain the comparatively
low mortality rates seen in PICUs (about 4 %) [25, 26].
Some cardiovascular consequences of anemia are specific
to children [27]. Congenital heart disease is frequently
observed in the PICUs. The resulting presentation of heart
failure and/or postoperative repair can directly impair DO2.
Children with cyanotic congenital heart disease can have Hb
concentrations as high as 20 g/dL, a rare occurrence in adults.
Inversely, certain pathologies frequently seen in adult
patients, such as coronary artery stenosis caused by atherosclerosis, are very rare in PICU.

261

 ong-Term Adaptive Mechanisms to Anemia
L
In the healthy human, anemia activates erythropoiesis almost
immediately, but a clinically significant increase in the blood
Hb level occurs only after a few days. In the critically ill
patient, this process may be delayed and the response to
usual stimuli may be blunted or absent. Strong stimuli for
erythropoietin production, such as tissue hypoxia, acute
blood loss and anemia are often present in the critically ill
and would be expected to increase erythropoietin production. Yet, paradoxically, erythropoietin plasma levels are
often lower than expected in these patients. Several factors
may be involved [28]. Certain inflammatory mediators may
decrease and even block the production of erythropoietin.
More particularly, in the systemic inflammatory response
syndrome (SIRS), which is present in >80 % of PICU
patients [29], high interleukin-1 (IL-1) and tumor necrosis
factor (TNF) levels can substantially attenuate erythropoietin
production [7, 30]. Moreover, the response to erythropoietin
is not optimal in patients with systemic inflammation, which
could explain why the response to erythropoietin is slow and
blunted in critically ill patients [31].
Iron metabolism is also affected in critically ill children.
In patients without iron deficiency, iron concentration in
blood is low despite increased iron storage, and there is less
free iron available for erythropoiesis [32]. In addition, a significant proportion of critically ill adults present some iron
(9 %), B12 (2 %) and/or folate deficiency (2 %) [7] These
observations explain (or at least partially explain) why anemia persists in critically ill patients, why their erythropoietin

levels are lower than expected, and why their response to
erythropoietin is not optimal. As a result, RBC transfusion is
frequently the only effective way to rapidly increase the Hb
level in critically ill patients whose response to usual medical
therapies (iron supplements, recombinant erythropoietin,
etc.) is suboptimal.

Management of Anemia in the PICU
Each year, ten million RBC units are transfused in the United
States of America [33] and 2.18 million units in the United
Kingdom (www.shotuk.org). Forty-nine percent of children
in a PICU for more than 2 days receive a transfusion during
their PICU stay [1]. It is clear that RBCs are useful: they
contain Hb, which transports O2 to cells, and cells require O2
to survive. Thus, it might seem reasonable to keep the blood
Hb level and hematocrit of critically ill patients in the normal
range. However, the safety of RBC transfusion has been
increasingly questioned over the last few years, mostly
because there is increased awareness among lay people and
physicians regarding the risk of contracting infections such
as HIV and hepatitis, and to some extent other potential


262

transfusion-related complications such as bacterial contamination and transfusion-related acute lung injury (TRALI). It
is less well recognized that transfusion of packed RBC units
may modulate the inflammatory process in recipients
(transfusion-­related immuno-modulation or TRIM), which
may increase the risk of developing nosocomial infections,

sepsis and MODS [34]. Thus, it is important to ask what the
risk/benefit and the cost/benefit ratios of RBC transfusion
are in critically ill children.

 ffects of Transfused RBC on Oxygen Delivery
E
Few studies have examined the role of Hb and RBC transfusions as a means of documenting and potentially alleviating
O2 supply dependence [27]. There is no doubt that RBC
transfusion increases global DO2, but does it increase DO2 to
specific organs and does it improve VO2? Global DO2 can be
normal in the presence of significant regional ischemia. A
number of studies describe the effect of transfused RBCs on
the distribution of systemic blood flow to specific organs
[14]. For example, Marik and Sibbald [35] showed that RBC
transfusion may cause gut ischemia among septic adults,
even if it increases global DO2. RBC transfusion can disturb
DO2 in the microcirculation (cellular DO2) by many mechanisms, such as increased blood viscosity, lower O2 release,
and shunted microcirculatory flow.
It is generally recommended that the hematocrit level be
maintained below 0.45 because blood viscosity increases
significantly over this threshold [36]. Messmer et al. [37]
have suggested that microcirculatory stasis and impaired
DO2 to tissues may be directly related to changes in Hb concentration. They theorize that normovolemic hemodilution
improves microcirculatory flow and DO2. Other authors have
suggested that hematocrit has limited effects on microcirculatory flow [38].
The microcirculatory effects of transfused RBCs may
also be attributable to release of inflammatory mediators
(cytokines, microparticles, lipids, etc.) in the supernatant of
stored RBCs and to increased activation of white blood cells
in packed RBCs [39, 40]. These mediators may initiate or

enhance an inflammatory reaction, which may result in
MODS [41]. They can also mediate vasoconstriction or
thrombosis of small vessels, causing local ischemia [42–44].
Leukocyte reduction should decrease the effects attributable
to white blood cells (e.g. cytokine release) and platelet-­
related microparticles [40], but the impact of microparticles
released by RBCs remains to be determined [39, 40,
45–47].
Transfused RBCs may also have properties that differ
from their in vivo counterparts. There are several age-related
changes that occur in stored RBCs. Characteristically, older
RBC units have lower levels of 2,3-DPG, which alters Hb
affinity for O2 [48]. Nevertheless, the decrease in 2,3-DPG
during storage appears to be of little clinical significance

M. Tucci et al.

since 2,3-DPG levels increase (in adults at least) to more
than 50 % of normal within several hours, and to normal levels within 24 h of transfusion [49].
Hb molecules interact not only with O2 and CO2, but also
with nitric oxide (NO), which is a key mediator of hypoxic
vasodilatation [50]. Free vascular Hb causes vasoconstriction, probably by fixing NO, and can substantially reduce
NO bioavailability [51]. Free Hb reacts up to 1,000 times
faster than Hb found within RBCs [52]. There is increasing
hemolysis over time in stored RBC units: the amount of free
Hb increases from 0.5 mg/dL in a 1 day-old RBC units to
250 mg/dL in a 25 day-old unit [53]. However, Hess et al.
[54] has shown that prestorage leukoreduction decreases free
Hb level by 53 %. The clinical impact of RBC hemolysis
remains to be determined in leukoreduced RBC units.

Storage-related changes in intra-erythrocyte Hb might be
problematic as well. S-nitrosylated Hb (SNO-Hb) is a protein that can bind, activate, and deploy NO [55]. Intra-­
erythrocyte SNO-Hb regulates small vessels tone and
regional blood flow. SNO-Hb reacts almost immediately to
local cellular hypoxia by releasing NO, resulting in local
vasodilatation. Conversely, RBCs bind more NO if local cellular VO2 seems adequate, leading to local vasoconstriction.
This function is almost immediately disturbed by storage
(<3 h) [15, 16, 56, 57], and most SNO-Hb is lost within
2 days of storage [55]. Decreased NO bioavailability from
RBC could explain the increased morbidity and mortality
reported in some patients after RBC transfusion [58].
RBC transfusions indeed improve global DO2, but this
does not always result in better regional DO2 and VO2 [59–
61]. RBC transfusions can impair regional blood flow and
cellular VO2 by many mechanisms: higher viscosity, vasoconstriction (cytokines, NO-Hb, free Hb) and low 2,3-DPG,
which may alter O2 release. As a consequence, transfused
RBCs may impair O2 availability and flow in the
­microcirculation, which may have adverse effects on tissue
oxygenation and cellular respiration [59–61].

I mmunologic Effects of Allogeneic RBC
Transfusions
Transfusion-related immuno-modulation (TRIM) is another
possible concern with regard to RBC transfusion [34]. Both
activation and suppression of the immune system have been
reported. Blood products such as RBC units, plasma and
platelet concentrates contain white blood cells that release
inflammatory mediators in concentrations proportional to
their number and to storage time. Several pro-inflammatory
molecules have been detected in stored non leukocyte-­

reduced RBC units, including complement activators [62],
cytokines [22, 42, 63], O2 free radicals [64, 65], histamine
[66], lyso-phosphatidyl-choline species [67] and other bioreactive substances that modulate the inflammatory process.
These white blood cells and inflammatory mediators may


19  Transfusion Medicine

trigger, maintain or accentuate SIRS in the recipients. SIRS
is common in critical care units, which may explain why
some data suggest that TRIM is one of the insults occurring
in the two-hit hypothesis and may be a risk factor for the
development of MODS in critically ill patients [68–70].
Transfusions of packed RBC units that are not pre-storage
leukocyte-reduced have resulted in clinically important
immunosuppression in at least some recipients [71–76]. In
particular, before the cyclosporin era, the transfusion of non
leukocyte-reduced RBC units was shown to decrease the
number of transplanted organ rejection episodes [77–79],
and improve renal and cardiac allograft survival [80–82].
This effect may be related to alterations in lymphocyte reactivity observed after blood transfusion. These immunosuppressive properties of non leukocyte-reduced blood products
may trigger (in contrast to the situation described above),
maintain or accentuate compensatory anti-inflammatory
response syndrome (CARS) in the recipients. CARS is also
common in critically ill patients [83].
Non leukocyte-reduced RBC units contain about 5 × 109
white blood cells per unit. The risk of TRIM may disappear
if the RBC unit is leukocyte-reduced, the latter defined as
less than 5 × 106 leukocytes per unit [2]. Pre-storage
leukocyte-­depletion is superior to reduction done by post-­

storage filtration at the bedside partially because pre-storage
leukocyte-reduction is usually done under more rigorously
controlled conditions and also because removal of white
blood cells prior to storage reduces the time-dependent accumulation of pro-inflammatory mediators in the supernatant
fluid [84–89]. Pre-storage leukocyte reduction is systematically undertaken in many countries (United Kingdom,
Canada, etc.); in 2009, 28 out of 33 American blood banks
(84.8 %) provided universal leukoreduction [90]. However,
pre-storage leukoreduction does not prevent the production
of all pro-inflammatory mediators detected in RBC units.
For example, stored RBCs shed microvesicles in the supernatant. This process is an integral part of the RBC ageing
process, is accelerated in stored RBC units and is not altered
by pre-storage leukoreduction. These microvesicles (ectosomes) contain lipids that can amplify an inflammatory reaction [39].
In summary, TRIM may be a risk factor for MODS in
critically ill patients [68–70], and may cause some immunosuppression, thereby increasing the risk of acquiring sepsis
and nosocomial infections [91–100], which may ultimately
result in higher mortality rates [70]. In spite of these concerns, the clinical impact of TRIM is still a matter of considerable debate [34]. Moreover the clinical effects of RBC
transfusion on the immunological responses of critically ill
children remain to be determined, and it is possible that pre-­
storage leukocyte reduction decreases or eliminates the risk
and/or the severity of TRIM [101–104]. More studies are
required to better determine if TRIM is indeed a clinically

263

significant problem, particularly when pre-storage leukocyte-­
reduced blood products are used.

 ength of Storage of RBC Units
L
RBC units can be stored up to 42 days. The normal average

life-span of RBCs is 120 days. RBC ageing is a normal process; it is slowed down in stored RBC units [105]. The storage lesion comprises the time-dependent metabolic,
biochemical, and molecular changes that stored blood products undergo over time. Storage lesions changes are observed
in all stored RBC units and are not normal processes. They
include increased levels in the supernatant of potassium, lactate, PCO2 as well as many inflammatory mediators (cytokines, lipids, CD40, etc.) associated with diminished levels
of sodium, low pH and PaO2. Storage-associated RBC abnormalities also include low ATP levels, increased hemolysis
with the release of free Hb, iron and lipids, a diminished 2,3-­
DPG concentration, less RBC deformability, increased RBC
adhesiveness and aggregation, disturbed intra-erythrocyte
Hb-nitric oxide (NO) interaction and regulation of small
blood vessels, etc. [106, 107].
Most of these changes appear within 2–3 weeks of storage. Currently, the average length of storage of RBC units
transfused to critically ill children is about 17 days in the
USA and Canada [108, 109]. It is unknown whether these in
vivo observations translate into clinically significant adverse
outcomes. More than 20 observational studies have reported
an association between age of blood and the incidence rate of
nosocomial infections [110–113], while others have found
no association [114–117]. Similarly some investigators
reported an association between increased RBC length of
storage and increased mortality in non-cardiac critically ill
adults [44, 110, 118–120], while others find no association
[121–123]. The same positive [124–128] and negative observations [115, 116, 129] have also been reported with respect
to mortality in cardiac patients.
Tinmouth et al. [106] stated, “There is strong laboratory
evidence suggesting that prolonged RBC storage may be deleterious”. The results of many observational studies indeed
suggest that an association exists between length of storage
and outcome, but the published data are equivocal, and it
must be underlined that observational studies overestimate
the real benefit of a treatment by 30–60 % [130]. It is important to emphasize that finding an association does not imply
a cause-effect relationship. Moreover, the number of RBC

units and the severity of illness are also associated with
increased mortality in transfused critically ill adults, and
they are associated to each other. There is clearly some confounding by indication [131], which further increases the
complexity of the relationship between RBC storage time
and adverse outcome, and which no multivariate analysis can
deconstruct. Only randomized clinical trials can uncouple
the relationship between severity of illness, number of


264

t­ransfusions and age of blood, and demonstrate a causeeffect relationship between RBC length of storage and
adverse outcome in transfused critically ill patients. Several
randomized clinical trials are presently addressing this question. The Age of Blood Evaluation (ABLE) study
(ISRCTN44878718) is enrolling 2,510 critically ill adults
since 2009 [132]. The Age of Red blood cell In Premature
Infants (ARIPI) study (NCT00326924), which recruited 450
premature newborns who were allocated to receive either
RBCs stored ≤7 days or transfusion therapy according to
standard practice, was completed in Spring 2011 [133]. The
“Red Cell Storage Duration and Outcomes in Cardiac
Surgery” (NCT00458783) is a single-center RCT comparing
outcomes in 2,800 patients allocated to receive RBCs stored
for less than 14 or more than 20 days. The Red Cell Storage
Duration Study (RECESS) (NCT00991341) is randomizing
1,434 cardiac surgery adult patients to receive either RBC
units stored ≤10 days or ≥21 days [134]. The age of blood in
children in PICU (ABC-PICU) study is in preparation and
plans to recruit more than 1,500 critically ill children. Until
hard evidence is available, the use of “fresh” rather than

“old” blood cannot be recommended for ICU patients [135].
Practice Patterns: Determinants of RBC Transfusion
Laverdière et al. [136] undertook a survey of pediatric critical care practitioners to investigate stated RBC transfusion
practices and clinical determinants that may alter transfusion
thresholds in critically ill children. The transfusion threshold
chosen by pediatric intensivists varied tremendously for a
given scenario, ranging from less than 7 g/dL to more than
13 g/dL. The following patient characteristics were statistically significant stated determinants of RBC transfusion: low
Hb concentration, primary diagnosis (bronchiolitis, ARDS,
septic shock, corrected tetralogy of Fallot), young age
(<2 weeks of age), low PaO2, high blood lactate level, high
PRISM score, active bleeding, thrombocytopenia, disseminated intravascular coagulation and emergency surgery. The
results of a survey published in 2004 undertaken among
European pediatric intensivists were similar [137].
While our beliefs affect what we teach and what we consider standard practice, the reality of what we actually do
(observed practice pattern) can be quite different. The same
group of investigators undertook an observational cohort
study of 303 children consecutively admitted to an academic
PICU and noted that 45 children (15 %) had received between
1 and 33 RBC transfusions each, for a total of 103 transfusions. The stated reasons for administering RBCs included
the presence of respiratory failure (84/103), active bleeding
(67/103), hemodynamic instability (50/103), blood lactate
level >2 mmol/L (10/103) or sub-optimal DO2 (6/103). In
many cases, more than one reason was specified, but in seven
cases, no specific reason was given [138]. In another cohort
study involving 985 consecutive critically ill children, the

M. Tucci et al.

most significant observed determinants of a first RBC transfusion were a low hemoglobin level, an admission diagnosis

of cardiac disease, an admission PRISM score >10 and the
presence of MODS during PICU stay [139]. The following
determinants of perioperative blood product—not only
RBC—transfusion were detected in a prospective cohort
study of 548 children undergoing cardiac surgery: younger
age, higher preoperative hematocrit, complex surgery, low
platelet count and longer duration of hypothermia [140].

 oal-Directed RBC Transfusion Therapy
G
Goal-directed RBC transfusion therapy is frequently advocated. Its basic principle is simple—a RBC transfusion
should be given with the aim of attaining a given “physiological” goal. Many goals are suggested in the medical literature. Some are related to biomarkers reflecting global O2
delivery (DO2) and/or O2 consumption (VO2): DO2, VO2,
blood lactate, Sv’O2 (mixed venous O2 saturation), ScvO2
(central venous SO2), O2 extraction rate, etc. Some are related
to regional (tissue) markers: near-infrared spectroscopy
(NIRS), regional or tissue SO2 (rSO2, StO2), regional O2
extraction rate, etc. Other goals have been considered, like
heart rate variability, plethysmographic variability [141] and
vascular endothelial growth factor levels [142]. Goal-­
directed RBC transfusion therapy might be the right clinical
approach. There are indeed good data supporting goal-­
directed therapy and using ScvO2 in unstable patients with
severe sepsis and septic shock [143, 144], but the role of
RBC transfusion in ScvO2-directed goal therapy is unclear.
There are no data supporting the use of other goals in other
circumstances. Moreover, there is no consensus on what the
best choice for a goal would be (maybe ScvO2 in patients in
severe sepsis and/or shock), nor any consensus on what
threshold should be used for these goals.

There is consensus that the Hb concentration should not
be the only marker used in the decision process to prescribe
a RBC transfusion. In addition to considering the Hb level,
many host-related and disease-related characteristics appear
to account for the practice variation observed in PICU. Goal-­
directed transfusion therapy is a useful concept, but the
appropriate goal remains to be determined and validated.
There is however some evidence with regard to three potential determinants that deserves further elaboration: threshold
Hb concentration, severity of illness (stable versus unstable
patients) and case-mix (cardiac patients).
 ed Blood Cell Transfusions in Non-cardiac
R
Patients
Stable Critically Ill Children
In critically ill adults, there were no clinical studies documenting the safety of maintaining the Hb at a lower concentration before Hébert et al. [70] published a landmark paper
in 1999. This randomized clinical trial involved


19  Transfusion Medicine

a­dministration of non leukocyte-reduced RBC units and
showed that a conservative strategy (RBC transfusion if the
Hb concentration dropped below 7 g/dL to maintain a level
between 7 and 9 g/dL) was as safe, in euvolemic critically ill
adults, if not safer than a liberal strategy (RBC transfusion
if the Hb concentration dropped below 10 g/dL to maintain
a level between 10 and 12 g/dL). An adjusted MODS score
as well as hospital mortality were statistically lower in the
former than in the latter group.
Data from the adult population are important, but cannot

be applied to pediatric patients without restriction because
many host characteristics are specific to critically ill children
and infants (different case-mix, normal range of Hb concentration that varies with age, different cardiovascular physiology, different energy requirements, better health status of
children prior to PICU entry, etc.). There have been two randomized clinical trials that evaluated RBC transfusion in
severely ill children. The first randomized clinical trial
included 106 African children hospitalized for a malarial crisis who had no congenital hemolytic anemia. In these
patients with hematocrit levels ranging from 0.12 to 0.17,
RBC transfusion did not improve mortality (1/53 vs 2/53) if
there was no respiratory or cardiovascular compromise [11].
The second randomized clinical trial, the Transfusion
Requirements In Pediatric Intensive Care Units (TRIPICU)
study, a large multicenter randomized non-inferiority clinical
trial, included only stable or stabilized patients [145]. In this
study, children were considered stable or stabilized if their
mean arterial pressure was not less than two standard deviations below normal mean for age and if the cardiovascular
support (vasopressors, inotropes and fluids) had not been
increased for at least 2 h [145]. It must be underlined that in
this definition of stable or stabilized patient, the respiratory
and neurological status were not taken into account. The
basic design of the TRIPICU study was quite simple. All
critically ill children who presented a Hb level ≤9.5 g/dL
within the first 7 days in the PICU were considered eligible
for the study; they were included if they were hemodynamically stable and had no exclusion criteria. Children were randomized either to receive a transfusion only if the Hb was
≤9.5 g/dL (liberal group) or to receive a transfusion only if
their Hb concentration was ≤7 g/dL (restrictive group). In
the liberal group (320 patients), transfusion aimed for a post-­
transfusion Hb level of 11–12 g/dL while the aim was 8.5–
9.5 g/dL in the restrictive strategic group (317 patients).
Only pre-storage leukocyte-reduced packed RBC unit were
used. The primary outcome measure was new/progressive

MODS and death; all deaths were considered cases of progressive MODS. The number of new/progressive MODS in
the restrictive and liberal groups where respectively 38 and
39. The 28-day of mortality was 14 in both groups. These
results suggest that a threshold Hb of 7 g/dL can be safely
applied to stable critically ill children. Accordingly, the

265

p­rincipal recommendation of the TRIPICU study was to
adopt “a restrictive transfusion strategy in PICU patients
whose condition is stable in the ICU”. One may challenge
this recommendation and argue that some patient populations can differ from those in TRIPICU and require more
RBC transfusions because they are sicker. Although not hard
evidence, subgroup analyses have thus far found no justification to give more RBC transfusion to stable critically ill children even if their PRISM score is higher [145], if patients
present with a septic states (sepsis, severe sepsis, septic
shock) [146], or if they are in PICU after undergoing a noncardiac surgery [147]. A before-after study also suggested
that a restrictive policy is safe in burn children [148].
Unstable Critically Ill Children
Most experts in critical care medicine and in transfusion
medicine believe that RBC transfusion is mandatory in hemorrhagic shock, regardless of the Hb concentration. The Hb
level observed while a patient is actively and acutely bleeding does not immediately reflect the volume of blood that has
been lost; thus, the Hb concentration is not the best marker to
guide transfusion on an emergency basis in such patients.
There is no consensus on what must be done in patients who
are unstable, but are not actively or acutely bleeding, like
critically ill patients with uncontrolled septic shock or
uncontrolled intracranial hypertension. Intensivists believe
that a higher threshold Hb concentration is required in unstable patients [136, 149]. Few hard data support this point of
view, other than two randomized clinical trials conducted in
adults with severe sepsis or septic shock by Rivers et al.

[143] and in children by de Oliveira et al. [144] These trials
suggest that intensivists should try to maintain the ScvO2
over 70 % and that RBC transfusion is required if fluid challenge (up to 80 mL kg within 6 h) and inotropes or vasopressors do not succeed in increasing the ScvO2 above 70 %.

 ed Blood Cell Transfusions in Cardiac Patients
R
Patients with impaired ventricular function cannot increase
their cardiac output as efficiently as other patients. Moreover,
even at rest, O2 extraction by myocardial cells is elevated,
which implies a lessened coping capacity when anemia
occurs. Thus, increasing the Hb level may be the only way
to increase DO2 and adequately support cardiac function in
these patients. Support for this notion can be drawn from a
retrospective study involving 1,958 adults who underwent
surgery and refused blood transfusion for religious reasons.
A substantially increased risk of death was associated with
a low preoperative Hb level in cardiac patients when compared to those without cardiovascular disease [8]. In practice, the threshold Hb concentration observed before RBC
transfusion is higher in the PICU during the postoperative
period of cases of pediatric cardiac surgery than in other
PICU patients [139].


266

Some recent publications question the statement that it is
safe to give RBC transfusions to cardiac patients. Laboratory
data suggest that RBC transfusion, even with fresh blood,
can disturb the capacity of RBCs to release and capture nitric
oxide, and to regulate the small blood vessels tone. Some
clinical data suggest that critically ill adults with cardiovascular disease need a higher Hb concentration [150], but other

data suggest that RBC transfusions can cause more ischemia
in patients with cardiac illness. For example, Murphy et al.
[151] reported a statistically and clinically significant association between RBC transfusions and ischemia in 8,518
adults transfused during post-operative care of a cardiac surgery: the adjusted odds ratio was 3.35 (95 % CI: 2.68–4.35).
This held true regardless of the hematocrit level before transfusion. Indeed, the proportion of patients with a hematocrit
<21 % who developed an ischemic episode was 1.9 % in non
transfused patients while it was 13.4 % in transfused patients.
In comparison, the proportion of patients with a hematocrit
over 27 % who developed an ischemic episode was 3.5 % in
non-transfused patients and 11.6 % in those who were
transfused.
What determinants to use in the post-operative care of
pediatric cardiac surgery patients and whether they are useful are matters of great debate. There is consensus that the
need for RBC transfusion in patients without cyanotic cardiac disease during the post-operative period must be
addressed separately from those of patients with cyanotic
heart disease. Many experts in pediatric cardiology believe
in maintaining elevated Hb levels in children without cyanotic heart disease and advocate Hb levels of 12–13 g/dL in
neonates and 10 g/dL in infants and children [152]. Other
experts in Britain and France do not share this view and
advocate lower Hb thresholds of 7–8 g/dL in stable children
with non-cyanotic heart disease [2, 153]. There is little evidence regarding this issue. In year 2009, Harrington et al.
[154] completed a scenario-based survey among Canadian
pediatric cardiac surgeons, cardiologists and intensivists in
order to ascertain their stated practice pattern with respect to
RBC transfusion during the post-operative care after a pediatric cardiac surgery. Two scenarios in the questionnaire
involved patients with non-cyanotic heart disease: a 6-day
old having undergone arterial switch surgery and a 5-month
old having undergone correction of a complete atrio-­
ventricular canal. Most respondents replied that a Hb lower
than 10 g/dL would prompt them to transfuse RBCs in these

patients. Their transfusion threshold increased Hb by 2.5 g/
dL if the patient was unstable, if he required ECMO, if active
bleeding occurred, or if the ScvO2 or the systemic blood
pressure dropped suddenly. In the TRIPICU study, 63
patients with non-cyanotic cardiac disease were enrolled in
the restrictive group and 62 in the liberal group [155]. New/
progressive MODS was observed in eight patients in the former and four patients in the latter (p = 0.36); there were two

M. Tucci et al.

deaths in each group at 28 days post-randomization. Thus,
the only presently available evidence from this subgroup
analysis suggests that a Hb level above 7 g/dL is safe for
critically ill children with non-cyanotic heart disease if they
are stable. A higher threshold Hb level is probably required
in unstable patients.
Neonates with cyanotic heart disease present Hb levels
that are significantly higher than normal – Hb concentrations
as high as 16–20 g/dL are frequently observed in these
patients. In the survey by Harrington et al. [154] described
above, two scenarios involved patients with post-operative
cyanotic heart disease: a 6-day old patient with tetralogy of
Fallot and a 5-month old with hypoplastic left heart syndrome – both underwent a Glenn procedure. Most respondents replied that they would prescribe a RBC transfusion
for these patients only if their Hb dropped below 12 g/dL.
Their transfusion threshold increased by 1.2 g/dL if the
patient became unstable, if an active bleeding appeared, if
the ScvO2 dropped suddenly, or if the lactate level was high.
Few clinical studies have addressed this question. A case
series of seven children with congenital cyanotic heart disease reported a decreased right to left shunt when increasing
the Hb concentration from 13.0 to 16.4 g/dL. The authors

specifically attributed the benefit seen to a decreased right to
left shunt and did not consider the possibility that benefit
could have been due to an increased VO2 [61]. Interestingly,
experience with bloodless surgery for complex cyanotic
defects suggests that cardiac surgery can be safely performed
with a lower level of Hb without evidence of increased risk
[156, 157]. Cholette et al. [158] published a randomized
clinical trial that included children with univentricular physiology among which 33 underwent a Glenn procedure and 27
a Fontan procedure: 30 patients were allocated to a restrictive strategy with a threshold for RBC transfusion of 9 g/dL
and 30 patients, to a liberal group with a threshold of 13 g/
dL. One death was observed in the liberal group. The median
lactate blood level was 1.4 ± 0.05 mmol/L in both groups.
Peak blood lactate was also almost identical (3.1 ± 1.5 versus
3.2 ± 1.3 mmol/L). However, the O2 extraction rate was
slightly higher in the restrictive group (31 % ± 7 % versus
26 % ± 6 %) with a difference that was statistically significant (p = 0.013), but not necessarily clinically significant.
These data suggest that it is safe not to give a RBC transfusion to patients with cyanotic cardiac disease as long as their
Hb level is over 9 g/dL.
The evidence that RBC transfusion improves the outcome
in children admitted to PICU after cardiac surgery is poor.
Some evidence in adults suggests that a RBC transfusion
may be detrimental. In spite of this, practitioners believe that
a higher Hb threshold is required in children with cardiac
disease, more so if a cyanotic heart disease is present. The
appropriate transfusion thresholds Hb for children during the
post-operative phase of cardiac surgery are unknown for


19  Transfusion Medicine

those with non-cyanotic as well as cyanotic heart lesions.
Only a subgroup analysis involving 125 patients from the
TRIPICU study has provided evidence which suggests that a
Hb level of 7 g/dL is well supported by non-cyanotic patients
and only one small randomized clinical trial conducted by
Cholette et al. [158] has suggested that a Hb level of 9 g/dL
is well tolerated by children with cyanotic heart disease.
More studies on RBC transfusion must be done in the field of
cardiac surgery.
Limiting Blood Product Transfusion
Whenever possible, it is always better not to administer any
blood product. The concept of bloodless medicine and blood
conservation are two aspects of blood management that all
intensivists should integrate into their clinical practice. Blood
conservation refers to limiting the volume of blood lost by
patients. Repetitive phlebotomy may contribute significantly
to blood loss (7.1 ± 5.3 mL/day, 34 ± 37 mL per PICU stay)
[159]. Limiting and consolidating blood tests, closed blood
sampling, use of pediatric blood collection tubes, and microanalysis techniques requiring small sample volumes
(<0.5 mL) can all be very effective ways to minimize blood
loss [160, 161]. The concept of bloodless medicine refers to
all the strategies that can be used to provide medical care
without allogeneic blood transfusion. Both concepts are discussed in greater detail in a separate chapter in this textbook.
Although bloodless medicine and blood conservation are
two concepts involving multiple strategies that should be
applied whenever possible, there are several instances when
a RBC transfusion must be considered. It is obvious that
more research must be undertaken to provide scientific data
before one can establish evidence-based guidelines.
Meanwhile, decisions related to transfusion should be driven

by physiological need rather than a specific Hb trigger, a
decision making process advocated by the National Institutes
of Health [162], the American College of Physicians [48]
and a group of Canadian experts [163]. Because markers of
“physiological needs” are not characterized in critically ill
patients, the Hb level is still pivotal to the decision making
process of intensivists who are considering RBC transfusion
[1, 136, 137, 164]. In practice, we recommend the following
strategy for hemodynamically stable critically ill children
without cyanotic heart disease [165]:
Blood gas machines should not be used for Hb estimation on
which to base a transfusion request.
RBC transfusion is required in most instances if the Hb concentration is <5 g/dL.
RBC transfusion is probably useful if the Hb concentration is
between 5 and 7 g/dL.
For Hb levels ranging from 7 to 9.5 g/dL, there appears to be
no overall benefit in transfusing RBCs.
No RBC transfusion is required if the Hb concentration is
>9.5 g/dL.

267

It is probably appropriate to consider a higher threshold
and/or to have a more aggressive RBC transfusion strategy in
critically ill children who are hemodynamically unstable or
who have significant cardiovascular disease. There is, however, no consensus on what this threshold should be. It is also
possible that a higher Hb concentration may be required
early in their course for patients with severe sepsis. Rivers
et al. [143] in adults and de Oliveira et al. [144] in children
showed that aggressive and early (first 6 h) goal-driven protocol therapy directed at attaining a ScvO2 greater than

70 mmHg (equivalent to 65 mmHg for mixed venous saturation) [166] improves outcome in patients with severe sepsis.
In the majority of patients, such early-goal therapy was
achieved only if the hematocrit was kept above 0.30 during
these six “golden” hours. The recommendations detailed
above this paragraph apply after these golden hours, once the
patient is stabilized. The decision to prescribe a RBC transfusion must be adapted to specific situations and must take
into account determinants other than the Hb concentration,
such as the severity of cases or the presence of mitochondrial
dysfunction (high blood lactate level), a frequent occurrence
in sepsis.

 he “Nuts and Bolts” of Packed RBC Transfusion
T
Packed RBC units are stored in a preservative anticoagulant
solution. CPD solution was previously a frequently used preservative that contains sodium citrate (C), citric acid, sodium
diphosphate (P) and dextrose (D). In this solution, the dextrose provides energy for RBCs through glycolysis, the phosphate is utilized by RBCs to generate adenosine triphosphate
(ATP) and the citrate chelates calcium, which inhibits coagulation, and is then metabolized to bicarbonate, which stabilizes the pH. Most countries have updated the constituents of
the solutions used. CPDA–1 (anticoagulant citratephosphate-­
dextrose-adenine) solution contains a higher
­concentration of dextrose than CPD (2 g vs 1.6 g/63 mL) and
some adenine (17.3 mg/63 mL). With this solution, ATP levels remain normal during 21 days of storage and decrease by
50 % after 35 days. Thus units with CPDA–1 can be stored
up to 35 days while units with CPD may only be stored for
21 days (28 days fir CPD-2). Additive solutions containing
more adenine, such as AS–1 (Adsol®), AS–3 (Nutricel®)
and SAG–M are being used with increasing frequency in
North American and European countries. The contents of
AS–1 and SAG–M are similar to that of CPDA–1 except that
they contain mannitol to decrease RBC lysis. Packed RBC
units stored in additive solutions have a shelf-life of

35–42 days, depending on country-specific regulations for
permitted storage (42 days in North-America, 35–42 in
European countries) [167, 168].
The volume of each CPDA–1 unit is 250 mL, which
includes 63 mL of preservative solution. Each unit may be
diluted with 75 mL of saline immediately prior to


268

a­ dministration to the patient (this decreases the hematocrit
from 0.70 to 0.55–0.60, allowing an easier administration).
The mean volume of each AS–1, AS–3 or SAG–M unit is up
to 350 mL, which includes 100 mL of preservative solution.
These units have a hematocrit of 0.55–0.60; so they do not
need to be diluted with saline prior to administration.
It is common practice to prescribe 10 mL/kg of packed
RBCs stored in CPDA–1 and it can be expected that this
should increase the blood Hb level by 2–2.5 g/dL if the
patient is not actively bleeding. It is frequently unrecognized
that these numbers hold true only for undiluted CPD/CPD–1
units: up to 15 mL/kg are required to get the same increase of
the Hb concentration with CPD/CPDA–1 units to which
saline (75 mL) has been added or RBCs stored in additive
solutions. However, the optimal prescription should consider
the Hb level prior to transfusion and should adjust the volume of the transfusion to attain a targeted Hb level. This can
easily be done if there is no active bleeding by using the formula below to calculate the exact amount (volume) of packed
RBCs that should be given:

M. Tucci et al.

RBC unit to be transfused (in liters) would be calculated as
shown below if the HbRBC unit is 19.5 g/dL (AS-3):
Volume = {(10 − 6.5 g / dL ) × 0.24 L} / {19.5 g / dL}

= 0.043 L = 43 mL.

One can also use the following formula:



Volume ( mL ) = {( Ht targeted − Ht observed )
(19.3)
× blood volume} / {Ht RBC unit }

In this latter formula, Httargeted is the hematocrit (Ht) targeted post-transfusion (for example, 0.30), Htobserved is the
most recently measured Ht of the patient (0.20), and HtRBC unit
is the average Ht in the packed RBC units delivered by the
blood bank.
In stable patients, RBCs should be administered on a unitby-­unit basis to minimize exposure to multiple donors and to
maintain the patient in the appropriate transfusion range. If
the volume of packed RBCs needed to reach the Hbtargeted is
greater than the volume of one unit of packed RBCs, blood
Volume (mL)={(Hb targeted − Hb observed )
should be transfused one unit at a time and the Hb measured
(19.1)
again prior to administration of additional packed RBCs.
× blood volume}/{Hb RBC unit }

Given the fact that Hb and Ht values equilibrate within 30

where Hbtargeted is the Hb concentration targeted post-­ min in transfused patients who are not actively bleeding
transfusion (for example, 10 g/dL), Hbobserved is the most [169], it would be appropriate to allow for this delay prior to
recently measured Hb concentration of the patient (g/dL), verification of post-transfusion Hb level. A packed RBC unit
and HbRBC unit is the average Hb concentration in the packed can be subdivided into smaller units—either half units or
RBC units (g/dL) delivered by the blood bank.
four to five aliquots—to avoid waste (Pedi-Pak®, Genesis
The Hb concentration of RBC units may vary from one BPS, is frequently used in North-America). Sterile preparacenter to another and according to the different preservative tion of these fractionated or partial units may allow for
solutions used. For non leukocyte-reduced RBCs in AS–3, remaining blood to be reserved for the same patient until the
the hematocrit is approximately 0.55, and the HbRBC unit con- expiry date, thus minimizing exposure to multiple donors. A
centration is about 19.5 g/dL (usual range: 18–21 g/dL). For packed RBC unit must be given within 4 h after leaving the
RBCs in CPDA–1, the hematocrit before dilution is about hospital blood bank. Fractionated units, which are prepared
0.65–0.75 and the HbRBC unit concentration is about 25 g/dL. in a sterile manner, can be kept as long as the original unit.
However, the Hb concentration does vary according to proTable  19.1 summarizes permissible choices of ABO/Rh
cessing methods (e.g. there is RBC loss with leukoreduction blood components according to recipient ABO/Rh blood
filtration, buffy coat removal and/or washing) and between groups. An ABO/Rh blood group is mandatory before any
units, variation related to the variability of donor Hb concen- blood component transfusion. In addition a cross-match
trations. Where possible, to use this formula accurately, it is (electronic or serologic according to institutional policy) is
preferable to know the average Hb concentration of the units required before a RBC transfusion. It takes 5–10 min to
supplied by the local blood bank.
ascertain the ABO and Rh status of a patient (type) and up to
The blood volume can be calculated according to the 60 min to complete pre-transfusion testing of a recipient
formula:
including ABO/Rh typing, antibody screening and cross
matching. In acute life-threatening situations requiring rapid
Total body blood volume = weight ´ blood volume (19.2) transfusion, there may not be sufficient time for complete
where weight is expressed in kg, and blood volume in liter/ pre-transfusion testing. In these situations, ORh− RBC and/
kg (0.08 L/kg for children aged <2 years, 0.07 L/kg for age or AB plasma should be administered. The risk of severe
2–14 years). For example, in a child weighing 3 kg whose hemolytic reaction to non cross-matched RBC units is low in
blood volume is 0.24 L (0.08 L/kg × 3 kg), who has a Hb patients who have never been exposed to allogenic RBCs
level of 6.5 g/dL and for whom the desired Hb level is 10 g/ (i.e. who have never been transfused or pregnant); however

dL (Hbtargeted), the volume of non leukocyte-reduced packed in emergency situations, a reliable medical history is often


19  Transfusion Medicine
Table 19.1 Choice of ABO and Rh groups for blood product
­administration in children

269

All packed RBC units (even leukocyte-reduced units)
contain fibrin, platelets and white blood cells, and must be
Blood product(s) to be transfuseda
filtered, using a standard blood bank filter with 180–260 μm
Recipient blood Red blood cells
pores. Some clinicians advocate using microaggregate filters
Plasma
group
Platelets b
(80  μm or less), but there are no studies that convincingly
O
O
O, A, B, AB
O, A, B, AB
show an advantage to their use.
A
A, O
A, AB
A, AB
Poiseuille’s law regulates the flow through a catheter:
B

B, O
B, AB
B, AB
Q’ = {π(P1–P2)r4/8 nL} where Q’ is flow (L/min), r is internal
AB
AB, A, B, O
AB
AB
radius, (P1–P2) is pressures difference, L is catheter length,
Rh+, Rh−
Not applicable Rh+, Rh−
Rh+
and
n is viscosity coefficient. Most of the resistance to flow
Rh−
Rh−
Not applicable Rh− c
attributable to a catheter is related to its radius (r4) and its
Based on data from Refs. [2, 170, 171]
a
The ABO subgroups suggested may not be appropriate in newborns length. Moreover, the high viscosity of packed RBC units
and young infants (<4 months) if maternal antibodies are present in the increases this resistance. It is therefore advisable that the
recipient. The above suggestions also do not apply for bone marrow biggest and shortest available catheter be used for RBC
transplant patients grafted from an ABO mismatched donor [170]
transfusion. A 14 G peripheral catheter in adults, a 20 G in
b
In emergency situations, if platelets of the recommended groups are
not available, units with low titers of Anti-A or anti-B should be infants, or even an intra-osseous catheter are acceptable;
selected, or alternatively the majority of the plasma should be removed 22 G catheters [174] or 1.9 Fr NeoPICC™ [175] are too
from the platelet concentrate

small unless the flow rate is decreased (<2.5 mL/kg/h) or the
c
Rh+ platelets can be given to an Rh− receiver when no Rh− platelets are intraluminal pressure generated by a pump is increased.
available. Anti-D immunoglobulins should then be considered, espeSignificant hemolysis can occur with intraluminal pressures
cially in women of childbearing potential
greater than 300 mmHg [174, 175]. Central vein catheters
are appropriate.
A RBC transfusion must be completed within 4 h of
unavailable. For patients who have been previously transfused or who are pregnant, it is difficult to give a precise removal of the unit from a monitored temperature controlled
figure as to the risk, and this will vary with individual patients refrigerator. No medication should ever be administered into
(e.g. number of previous transfusions, availability of previ- the same intravenous access and it is inappropriate to comous records, nature of the underlying disease like immuno- bine transfusion RBCs with a solution that contains dextrose
suppressed patient versus a sickle cell patient). The physician (risk of hemolysis), Ringer lactate or calcium (risk of coagumust weigh risks and benefits. However, in truly life-­ lation) [176]. Only physiologic saline (0.9 % NaCl) is
threatening situations, most physicians would proceed with compatible.
Patients should be closely monitored while receiving
transfusion of non cross-matched blood. If large amounts of
uncross-matched packed RBC units are transfused, the hos- blood products and transfusion must be immediately stopped
pital blood bank might recommend that similar units con- if a transfusion reaction is suspected (see section on reactinue to be administered for a while (a protocol is usually tions to blood product transfusion at the end of this chapter).
implemented to deal with massive transfusion in most Patient clinical data as well as information regarding the
blood products received must be detailed in the hospital
hospitals).
RBC units are stored at 1–6 °C and therefore represent a chart. If a transfusion reaction is suspected, it is important
significant risk of hypothermia. All units are warmed to not to dispose of the remaining blood product as well as any
room temperature (about 20 °C) prior to administration. filters and tubing and to forward all items to the blood bank.
Warming to body temperature (37 °C) should be considered All possible severe transfusion reactions must be reported to
when significant volumes are given rapidly. In practice, the local blood blank. In some instances, it may be indicated
packed RBC units are warmed to 37 °C before transfusion to obtain a blood culture from the patient and from the
to a small patient (<10 kg) or if the amount given constitutes remaining product, and to assess the patient for hemolysis.
>20–30 % of the recipient’s blood volume. In other situations (i.e. larger child, slower infusion rate), the blood will Whole Blood
warm sufficiently at room temperature while being infused. Whole blood stored for longer than 24 h contains few viable
Warming packed RBCs decreases viscosity (7 % decrease platelets. In addition, levels of Factors V and VIII (the labile

for each 1 °C increase), thus lowering the resistance through coagulation factors) decrease with storage at 4 °C. Levels of
the catheter used; the clinical relevance of this remains to be the other clotting factors are however well maintained at 4°
determined. Standard blood-warmer must be used to rise the storage. Whole blood can be reconstituted by combining one
temperature of whole blood or packed RBC units, not unit of packed RBC with a compatible unit of fresh frozen
micro-­waves oven because they can cause severe hemolysis plasma [84]. Worldwide, most blood suppliers do not routinely provide whole blood. However, the transfusion of
[172, 173].


270

whole blood could be considered in the following four situations: (1) hemorrhagic shock; (2) exchange transfusion in a
newborn; (3) administration of an autologous unit (i.e. blood
collected from the patient a few days or weeks prior to re-­
infusion at the time of elective surgery); (4) administration of
blood donated by a family member and dedicated to a given
patient. Some investigators have claimed that the use of fresh
whole blood is associated with less post-operative blood loss
[177]. Whole blood less than 48 h old is systematically used
in some hospitals for cardiac surgery, mostly to prime the
cardiopulmonary bypass circuit [152]. However a randomized clinical trial has shown that “the use of fresh whole
blood for cardiopulmonary bypass priming has no advantage
over the use of a combination of packed red cells and fresh-­
frozen plasma during surgery for congenital heart disease”
[178]. In other situations, it is preferable to administer RBC
and plasma separately or, in the case of exchange transfusion, as reconstituted whole blood, if both RBC and coagulation factors are required.
Specific Types of Packed RBC Units
While in most instances, standard packed RBCs can be
safely used, there exist various other available products indicated for specific clinical situations including washed, irradiated, dedicated, autologous and cytomegalovirus (CMV)
seronegative units.
Washed units. – Washed packed RBC units have had more

plasma extracted than usual. The hematocrit depends entirely
on how much saline is used to reconstitute the solution after
washing; it can be as high as 0.70–0.80, but usually is
adjusted to give a hematocrit of 0.55–0.60. The volume of
washed RBC units depends on the hematocrit. It generally
takes 2 or 3 h to complete the washing process and these
units must be used within 24 h after entering the unit to begin
washing, unless processed with newly available equipment
that maintains a close system and thus allows longer
(7–14 days) storage post-washing. Washed RBC units can be
used to prevent transfusion reactions in patients who have
presented severe or recurrent allergic reactions. Some practitioners use washed RBC units because they believe they are
free of potassium. However, strong hemolysis is observed in
washed RBC units; the concentration of potassium units
increased rapidly after they are washed, and get to the pre-­
washed potassium concentration within 24 h [179].
Irradiated units. – Patients at risk of contracting
transfusion-­associated graft versus host disease (TA-GvHD)
must receive gamma-irradiated cellular blood components.
Susceptible patients include those with congenital
­immunodeficiency, patients receiving immuno-suppressive
therapy, recipients of directed transfusions from family
members and possibly pre-term infants [152]. However, irradiation does lead to an increased leakage of potassium from

M. Tucci et al.

the RBCs. The impact of this problem can be minimized if
the blood product is administered soon after irradiation.
Autologous units. – A packed RBC unit is autologous
when it was collected from the receiver. In the pediatric population, this is possible with older children who are healthy

enough to give their own blood a few weeks before elective
surgery. It is frequently believed both by lay people and by
caregivers that the transfusion of autologous RBC units is
absolutely safe. However, there are some complications that
may occur with autologous transfusion, including bacterial
contamination, transfusion overload and transfusion error.
CMV negative units. – CMV may be transmitted by the
transfusion of cellular blood components, and this may cause
serious infection in certain categories of transfusion recipients. Because more than 50 % of donors are CMV positive,
it is impossible to procure CMV seronegative blood products
for all recipients. This blood product is therefore usually
reserved for CMV negative future transplant recipients or for
already transplanted patients whose donor was CMV negative and who are themselves CMV negative. CMV is transmitted by white blood cells and consequently the risk of
contracting a CMV infection is significantly decreased (but
not absent) with leukocyte-reduced units.

Transfusion of Frozen Plasma
Plasma for transfusion is prepared from a whole blood
donation by separation following centrifugation. Larger
volumes of plasma may be collected using automated
apheresis techniques. A typical unit of plasma has an
approximate volume of 250 mL if obtained from a whole
blood donation or approximately 500 mL when obtained by
plasmapheresis.
Immediately following collection from a normal donor,
plasma contains approximately 1 unit/mL of each of the
coagulation factors as well as normal concentrations of other
plasma proteins. Coagulation Factors V and VIII, known as
the labile coagulation factors, are not stable in plasma stored
for prolonged periods at 1–6 °C; consequently plasma is usually stored frozen at −18 °C or lower. Plasma frozen within

8 h of collection, known as fresh frozen plasma (FFP), contains about 87 % of Factor VIII present at the time of collection and, according to standards in most countries, must
contain at least 0.70 UI/mL of Factor VIII. Several countries
also use plasma frozen within 24 h of collection, known as
frozen plasma (FP). Factor VIII levels in frozen plasma are
approximately 70–75 % of the levels present at the time of
collection. The levels of Factor V as well as the levels of
other coagulation factors are not significantly decreased
from baseline in plasma frozen within 24 h of collection
[180, 181].


19  Transfusion Medicine

FFP and FP units are collected from a single donor, while
units of virus inactivated frozen plasma—solvent detergent
FFP (SD-FFP) (Octaplas, Octapharma) and methylene-blue
treated FFP (MB-FFP)—are constituted from a pool of frozen plasma collected from approximately 700 donors; the
SD process is used for inactivation of lipid-enveloped
viruses. SD plasma is not currently licensed in the USA, but
it is licensed and available in Europe. In some countries, only
FP is available, but in many countries including the USA
fresh FP is still available in 2011. Depending on the exact
temperature at which plasma is stored, applicable national
requirements/regulations and the precise product, frozen
plasma can be stored from 3 to 24 months.

Indications for Frozen Plasma Transfusion
In 2006, approximately four millions unit of plasma were
transfused in the USA [182]. In 2010, 292,884 FFP units and
57,487 SD-FFP units were transfused in the United Kingdom

(www.shotuk.org). There is broad, general consensus that
the appropriate use of FFP, FP and SD-FFP is limited almost
exclusively to the treatment or prevention of clinically significant bleeding due to a deficiency of one or more plasma
coagulation factors. Such situations potentially include the
presence of (1) a diminution of coagulation factors due to
treatment with vitamin K antagonists, (2) severe liver disease, (3) disseminated intravascular coagulation (DIC), (4)
massive transfusion, (5) warfarin anticoagulation-related
intracranial hemorrhage, (6) isolated congenital coagulation
factor deficiencies for which a safer and/or more appropriate
product does not exist [183]. A panel of experts could not
“recommend for or against transfusion of plasma for patients
undergoing surgery in the absence of massive transfusion”
[183]. The same experts could not “recommend for or
against” a plasma/RBC ratio of 1:3 or more (<1:3) in trauma
patients requiring massive transfusion [183].
Plasma exchange with FFP, FP or cryosupernatant as the
replacement fluid is the standard therapy for thrombotic
thrombocytopenic purpura (TTP). Although no hard evidence supports this, some physicians also advocate plasma
administration or exchange transfusion to treat patients with
hemolytic uremic syndrome (HUS) who develop neurologic
complications [184]. Plasma exchange may be used to treat
Guillain-Barré syndrome [185] and acute disseminated
encephalomyelitis (ADEM) [186], although intravenous
immunoglobulins may be a better option [187]. Plasma
exchange is also currently being studied as a therapeutic
measure in sepsis [188, 189].
There is also a consensus among the experts developing
guidelines that FFP and FP are not indicated in the following
situations:

271

1. Intravascular volume expansion or repletion (where crystalloids, synthetic colloids or purified human albumin
solutions are preferred) [84];
2. Correction or prevention of protein malnutrition (where
synthetic amino acid solutions are preferred);
3.Correction of hypogammaglobulinemia (where purified
human immunoglobulin concentrates are preferred);
4.Treatment of hemophilia A or B and von Willebrand
disease (where desmopressin, virus-inactivated plasma-­
derived or recombinant factor concentrates are
preferred);
5. Treatment of any other isolated congenital procoagulant
or anticoagulant factor deficiency for which a virus-­
inactivated plasma-derived or recombinant factor concentrate exists;
6. Treatment of hemolytic uremic syndrome (HUS) unless
plasma exchange is indicated;
7. As replacement fluid in therapeutic apheresis procedures
for disorders other than TTP/HUS unless proven to be
beneficial.

 he “Nuts and Bolts” of Frozen Plasma
T
Transfusion
The amount of FFP of FP initially prescribed ranges from
10 to 20 mL/kg. The coagulation profile should be verified
before further plasma administration. Close monitoring of
the respiratory and hemodynamic status of the recipient is
mandatory because plasma transfusion is associated with
increased risk of developing ALI and transfusion-associated circulatory overload (TACO) [190]. It may be necessary in certain patients to repeat transfusion or to initiate a

continuous perfusion (at a rate of 10 mL/kg/h), if there is
active bleeding. Repeated measurement of the activity of
the coagulation cascade is the best way to determine
whether more plasma is required. Indications for continuing plasma administration are the same as for starting
plasma.
FFP and FP can be thawed in less than 10 min using
microwave ovens specifically manufactured for this purpose.
A unit of FFP/FP must be administered within 4 h after thawing. Standard blood administration filter must be used.
Plasma prepared from whole-blood derived FFP expires as
FFP 24 h after thawing if kept at 1–6 °C, but it can be converted to thawed plasma. This product expires 5 days after
thawing if stored at 1–6 °C. Thawed plasma has reduced
level of FVIII and is not suitable for Factor VIII replacement.
However, concentrations of remaining factors are clinically
adequate for transfusion to other patients [168].


272

Transfusion of Platelets

M. Tucci et al.

with an active hemorrhage falls below 50,000/mm3 [196], or
if the hemorrhage is severe and there is platelet dysfunction,
Three mechanisms combine their effect to stop bleeding as occurs frequently following cardiopulmonary bypass
from an injured vessel: (1) vasoconstriction, (2) platelet [197]. Many intensivists consider that the risk of pulmonary
aggregation to form a plug and (3) plug stabilization by a hemorrhage is significant in mechanically ventilated patients
fibrin clot [191]. A low platelet count and/or significant if the platelet count is <50,000/mm3, and most will prescribe
platelet dysfunction therefore places a patient at risk for platelet transfusion in such instances (although this has never
bleeding because of an impaired ability to form a platelet been substantiated by clinical studies). A threshold of

plug. Platelet dysfunction is common in ICU. In most 100,000/mm3 is generally recommended for patients with
instances, it is attributable to toxins, drugs (for example, multiple trauma, central nervous system injury [196], or for
salicylate, nitric oxide), exposure to extracorporeal circula- patients on extracorporeal membrane oxygenation (ECMO)
tion and renal failure; rarely, unusual causes such as certain [2, 84]. In patients with thrombocytopenia due to decreased
inherited diseases can be involved [191]. Treatment of plate- platelet production, prophylactic platelet transfusion should
let dysfunction, when required, includes administration of be considered if the platelet count is <10,000/mm3 or if there
certain drugs (for example, antifibrinolytic agents) and/or are additional risk factors for bleeding.
platelet transfusion.
The administration of a large amount of crystalloids,
Thrombocytopenia is defined by a platelet count packed RBCs and/or whole blood (more than one blood vol<150,000/mm3. The prevalence of ICU-acquired thrombocy- ume) can have a dilutional effect on the platelet count and
topenia is 44 % in critically ill adults [192]. Causes of throm- warrants close monitoring [198, 199]. Platelets are associbocytopenia in ICU are multiple and include sepsis [193], ated with a sevenfold increased risk of acute transfusion
DIC, massive transfusion, bone marrow histiocytic hyperpla- reaction compared to RBC <www.shotuk.org>.
sia with hemophagocytosis (acquired hemophagocytosis
Platelet transfusion should not be used for the treatment
syndrome) [193, 194], as well as drug-related and heparin-­ of idiopathic thrombocytopenic purpura except in the presinduced thrombocytopenia [195]. Because correction of ence of intracerebral or life-threatening bleeding [200, 201].
thrombocytopenia has been shown to be associated with Platelets are also contra-indicated in cases of ­heparin-­induced
reduced mortality [192], it is reasonable to administer plate- thrombocytopenia and of thrombotic thrombocytopenic purlet transfusions to critically ill patients with a low platelet pura [196]. Alternatives to platelet transfusion, such as
count. However, the threshold below which a platelet trans- DDAVP or antifibrinolytic agents, should be considered as
fusion should be given is a matter of debate.
first choice therapies when appropriate [202].
Platelet concentrates are prepared from whole blood
donations or by apheresis collections. Platelet concentrates
prepared from whole blood contain about 55 × 109 platelets The “Nuts and Bolts” of Platelet Transfusion
per unit, plus 50 mL of plasma, a small quantity of RBCs and
about 108 white blood cells/unit. Apheresis platelet concen- The amount of platelet concentrate (either whole blood
trates contain about 300 × 109 platelets per unit, plus 250– derived or apheresis platelets) generally prescribed ranges
300 mL of plasma, up to 5 mL of RBCs and about 109/unit from 5 to 10 mL/kg for infants weighing less than 10 kg. For
white blood cells. In many countries (Canada, United older children weighing more than 10 kg, the usual starting
Kingdom, etc.), but not in the USA, all platelet units are dose is 1 whole blood derived unit per 10 kg (i.e. 1 unit for
leukocyte-­reduced pre-storage, either by filtration or (in the 11–20 kg child, 2 units for 21–30 kg child, etc.) or approxicase of apheresis platelets) as part of the automated process- mately 10 mL/kg up to a maximum of 1 pool of platelets if

ing. This decreases significantly the risk of HLA alloimmu- using apheresis or pre-pooled platelets. It can be expected
nization, non hemolytic febrile reactions and the transmission that this should increase the platelet count by 50,000/mm3
of CMV. Both types of platelet concentrates are stored at unless there is increased platelet consumption [84]. It is stan20–24 °C for up to 5 days. In many countries, bacterial detec- dard practice to give no more than five units of whole blood
tion is performed to decrease the risk of bacterial derived platelet concentrates or one apheresis platelet unit
per transfusion. The recommended infusion time is 60 min
contamination.
or less. All platelet units must be administered within 4 h
after delivery from the blood bank.
Indication for Platelet Transfusion
Platelets possess intrinsic ABO antigens and extrinsically
absorbed A and B antigens [203]. Nevertheless ABO incomIn 2010, 246,962 platelet units were transfused in the United patible platelets (i.e. platelets with A and/or B antigens given
Kingdom (www.shotuk.org). There is consensus that a plate- to a donor with a corresponding antibody) are usually clinilet transfusion is indicated if the platelet count of a patient cally effective. However there are several reports of acute


273

19  Transfusion Medicine

intravascular hemolysis following the transfusion of platelet
concentrates containing ABO antibodies incompatible with
the recipient’s RBC [203, 204]. Therefore ABO-matched
platelets should be used in pediatric patients especially for
neonates and small children where the volume of plasma
may be relatively large with respect to the patient’s total
blood volume. If ABO-matched platelets are not available,
units with plasma compatible with the recipient’s RBCs
should be chosen. If this is also not possible, units with low
titers of anti-A or anti-B should be selected or alternatively
the plasma can be removed from the platelet concentrate (i.e.
use a volume reduced platelet concentrate) [2]. Platelets do

not carry Rh antigen, but concentrates contain RBCs in numbers sufficient to sensitize the recipient. An anti-D vaccine
(Win Rho SDR®) should be given if the recipient is a Rh−
woman of childbearing potential and the donor is Rh+ [2].
Each 120 mcg of Rh-immunoglobulin covers 12 mL whole
blood (6 mL RBC) and lasts approximately 21 days [205].
Tobian et al. [206] reported that the incidence of allergic
transfusion reactions to unmanipulated apheresis platelets is
5.5 %, and that concentrating and washing reduced this incidence to 0.5 %. Recipients of HLA-matched platelets should
receive irradiated platelets in order to prevent graft versus
host disease.

Serious Hazards of Transfusion

Table 19.2  Reactions and complications related to blood product
transfusions
Frequency
1. Early onset reactions (<24 h)
 Transfusion-related acute lung injury
(TRALI) [207]
 Transfusion associated circulatory overload
(TACO) [207]
  Isolated hypotensive reaction [207]
  Major allergic reaction (anaphylaxis) [207]
  Minor allergic reaction [207]
  Febrile non-hemolytic reaction [207]
  Acute hemolytic transfusion reaction [207]
  ABO incompatibility [208]
2. Early onset complications of massive
transfusion [199]a
 Coagulopathy

 Thrombocytopenia
 Hypothermia
 Hypocalcemia, hypomagnesemia, citrate
toxicity
 Hyperkalemia
 Metabolic alkalosis by citrate toxicity, metabolic
acidosis
3. Late onset complications of transfusion
  Delayed hemolytic reaction [207]
  Allo-immune thrombopenia
  Post-transfusion purpura [207]
 Infections
 Transfusion associated graft versus host disease
(TA-GvHD) [214]
4. Early and late deaths [215]

1/31,960
1/34,091
1/102,273
1/11,117
1/100
1/50–1/200
1/26,914
1/800,000

Frequent
Common
Common
Common
1/20

Rare

1/255,682
Unknown-rare
1/85,227
See Table 19.3
1/1,000,000

Labile blood products (RBC units, frozen plasma, platelet
1/2,845,459
concentrates and cryoprecipitate) can cause early onset or a
Definition of massive transfusion : administration of more than one
late onset reactions and complications (Tables 19.2 and 19.3) blood volume of blood products within a 24 h period
[197]. By definition, immediate reactions occur while the
transfusion is being given or within 24 h after the end of the
transfusion. Late reactions and complications appear days, Acute Reactions
weeks or even years later. Severe reactions probably attributable to the transfusion of a blood product should be reported Any unexpected or unexplained change in the clinical condito the hospital blood bank.
tion of a patient during a transfusion or up to 24 h afterwards
The transfusion of a blood product can result in early as should be considered (and evaluated) as possibly being due
well as late onset death. The overall mortality rate attributed to an acute transfusion reaction, and should be reported to
to the transfusion of a blood component dropped to the local blood bank [217].
1/2,845,459 per transfusion in the United Kingdom in 2008
(Serious Hazards of Transfusion Group: (www.shotuk.org). Transfusion-Related Acute Lung Injury (TRALI)
[205]. The risk is higher with platelet concentrates: in 2000, TRALI is now a well-recognized reaction to transfusion of
the mortality observed in Canada and attributed to the trans- blood products and also one of the most serious. A TRALI is an
fusion of a blood product was 2.2 per 100,000 RBC units and acute lung injury (ALI) that appears during or within 6 h after
6.3 per 100,000 platelet pools [209]. The Center for Biologics the end of a transfusion. A panel of experts created a list of
Evaluation and Research of the Food and Drug Administration diagnostic criteria of TRALI that is detailed in Table 19.4. The
receives approximately 60–70 transfusion-related fatality criterion of “no pre-existing ALI before transfusion” means
reports per year [216]. The 13 deaths reported in 2010 by the that TRALI cannot be diagnosed when an ALI is already pres“Serious Hazards Of Transfusion” (SHOT) system of the ent. Clinically, TRALI resembles ARDS and involves respiraUnited Kingdom were caused by TACO (7), TRALI (1), tory symptoms such as hypoxemia, dyspnea and frothy sputum

hypotension (1), anaphylactic reaction (1), hyperhemolysis as well as hypotension, tachycardia and fever [216]. Chest
(1) and under-transfusion in a case of hemorrhagic shock.
radiograph findings are also similar to those seen in ARDS and


274
Table 19.3 Infections
transfusion

M. Tucci et al.
potentially

Infection
HIV (AIDS) [207]
Hepatitis A [209]
Hepatitis B b [210]
Hepatitis C [207]
Other hepatitis (D, E, etc.)
HTLV (Health Protection Agency)
<www.hpa.org.uk>
Cytomegalovirus [209]
Parvovirus B19 [207]
TTBI (platelet) [209]
TTBI (RBC unit) [209]
Other infections c

caused

by

blood

product

Risk per transfusiona
1/4,000,000
<1/10,000,000
1/282,000–1/357,000
1/2,800,000
Unknown-rare
1/17,000,000
Unknown-rare
1/5,000–1/20,000
13–44/100,000 platelet pools
0.02/100,000 RBC units
Unknown

HIV human immuno-deficiency virus, HTLV human T-lymphocyte
virus, RBC red blood cell, TTBI transfusion transmitted bacterial
infection
a
Risk per transfusion of blood product: these figures are applicable only
in countries where virus testing is systematically performed (testing for
HIV, hepatitis B and C is systematically performed in less than 45 % of
members states of the World Health Organization [211])
b
The risk for transfusion-transmitted chronic HBV disease in Canada
was estimated to be 1 in 2,240,000 transfusion in year 2003 [209]
c
Other infections: zoonoses such as babesiosis [210], Colorado tick

fever [210], Chagas disease [211], dengue [210], malaria [210], variant
Creutzfeldt-Jacob disease [212], West Nile virus [213], etc.
Table 19.4  Diagnostic criteria of TRALI
The following diagnostic criteria of transfusion-associated acute
lung injury (TRALI) were adopted during a Consensus Conference
held in Toronto in 2004 [218]
 Diagnostic criteria of TRALI: all six criteria must be present in
order to diagnose a TRALI
   1. Acute onset of acute lung injury (ALI)
  2. Hypoxemia
   Research setting:
    PaO2/FiO2 ratio ≤300
    or SpO2 <90 % on room air
   Nonresearch setting:
    PaO2/FiO2 ratio ≤300
    or SpO2 <90 % on room air
     or other clinical evidence of hypoxemia
   3. Bilateral infiltrates on frontal chest radiograph
  4. No evidence of left atrial hypertension (i.e., circulatory
overload)
   5. During or within 6 h of transfusion
   6. No temporal relationship to an alternative risk factor for ALI
  Diagnostic criteria of possible TRALI:
  1. ALI
   2. No preexisting ALI before transfusion
   3. During or within 6 h of transfusion
  4. A clear temporal relationship to an alternative risk factor for ALI

show generalized opacities. In 90 % of cases, the reaction
appears within 1–2 h after a transfusion is started. HLA antibodies and/or granulocyte antibodies are positive in 65–83 %

of tested donors [216, 219]. Respiratory symptoms usually disappear within 48–96 h, which is different from the progression
typically seen in ARDS [220]. All blood products containing
some plasma can cause a TRALI, but frozen plasma (50 %)
and packed RBC units (31 %) are more frequently involved
than platelet concentrates (17 %) [216].
The incidence of TRALI was between 1/1,000 and
1/8,000 transfusions in the 90s and the early 2000 [221–223].
A recent surveillance study completed in 2010 reported an
incidence rate of 1.8 TRALI per 100,000 transfusions in
Canadian children [224]. In this study, three out of the four
cases of TRALI occurred in PICU patients. Furthermore,
two cases occurred in neonates who underwent cardiac
surgery, raising the possibility that these patients are at
­
greater risk of TRALI.
The mechanisms involved in the physiopathology of
TRALI are still being debated. The most popular hypotheses
include: (1) a reaction between donor antibodies (anti-­
granulocyte, anti-HLA class I or II) and recipient antigens
that initiates an inflammatory reaction in the lungs; (2) the
neutrophils of a recipient primed by surgery, trauma or an
infection overreact when exposed to inflammatory activators
(anti-leukocyte, biologically active lipids, etc.) that are either
present in the donor’s blood or that were produced during
storage [225, 226]. Recent studies suggest that the two theories might be somewhat linked [227]. This has lead to the
development of a unifying model (the threshold model) by
Bux et al. [228] According to this model, the level of priming
of neutrophils, either directly or through activation of the
pulmonary endothelium, by a patient clinical condition and

by substances (including antibodies) present in the transfused component, is responsible for triggering TRALI in a
recipient.
The treatment of TRALI involves cessation of the blood
product deemed responsible and is otherwise the same as
that of ARDS. When a TRALI is suspected, the transfusion
must be stopped immediately, and supportive treatment must
be started. Oxygen, mechanical ventilation and fluids may be
required [229]. Diuretics are not recommended because they
increase the risk of severe hypotension [230].
In some countries like the United Kingdom, Canada and
USA (American Red Cross), blood collected from multiparous women is not used for transfusion, but sent to fractionation (production of albumin, IVIg) and/or a policy of
preferential use of male donors has been implemented, the
hypothesis being that this should reduce the exposure of
blood receivers to donor antibodies (anti-granulocyte, anti-­
HLA) [231–233]. In the United Kingdom, provision of male
plasma was associated with a reduction in TRALI reports
from 36 in 2003 to 23 in 2004 and 2005 and 10 in 2006
[219]. The mortality rate of TRALI is approximately 6 %
[221], but the prognosis is good in most cases. In survivors,
resolution is usually rapid (within 96 h) and there are no


19  Transfusion Medicine

long-term sequelae [230]. However hypoxemia and pulmonary infiltrates persist more than 7 days in some patients
(20 %) [229].
The diagnostic criteria advocated by the panel of experts
in 2004 [218] exclude the possibility that a TRALI appears
in a patient who already presents an ALI or an ARDS when
a RBC transfusion is initiated, which is frequent in the PICU.

There is indeed some evidence that a TRALI should also be
considered in some patients with ALI/ARDS before a transfusion if their respiratory dysfunction deteriorates significantly during or after a transfusion. Marik et al. [234]
suggested expanding the definition of TRALI in ICU to ALI/
ARDS observed within 72 h after the transfusion of a blood
product: they reported that such “delayed TRALI syndrome”
occurred in up to 25 % of critically ill adults receiving a
blood transfusion. Church et al. [235] also reported an association between the transfusion of plasma and/or packed
RBC units and ALI/ARDS. The bioactive substances contained in packed RBC and plasma units can cause or add to
the severity of cases of ALI/ARDS [235–237]. Further
­investigation is required to better characterize the epidemiology, the mechanisms and the clinical impact of transfusionrelated delayed TRALI syndrome in PICU.

275

caused by a bradykinin modulated metabolic reaction elicited when the blood product is exposed to a negatively
charged surface like a transfusion filter. Patients receiving
angiotensin conversion enzyme inhibitors as well as patients
with an abnormal bradykinin catabolism, a common occurrence in cases of sepsis, are also at risk [197]. Hypotensive
reactions usually appear quite soon after the transfusion is
initiated and in most instances, there is no fever, although
some flushing has been described. These reactions are more
frequent after transfusion of platelet concentrates [238]. Pre-­
storage leukocyte reduction seems to decrease their incidence, although it does not eliminate them entirely [239].
Close monitoring of all patients receiving angiotensin conversion enzyme inhibitors is required.

Fever
Fever is the most frequent reaction to a blood product transfusion. It is not dangerous unless it is caused by a hemolytic
reaction or a bacterial contamination. Its frequency after
transfusion of a packed RBC unit is about 1 % [163, 240] and
can be as high as 10 % after transfusion of platelet concentrates [241]. A febrile non-hemolytic transfusion reaction
(FNHTR) is defined as a de novo rise in temperature equal to

or greater than 1 °C that cannot be explained by the patient’s
clinical condition (i.e. other causes of fever must be ruled
Transfusion-Associated Circulatory Overload
(TACO)
out). The fever can be accompanied by dyspnea, tachycardia,
TACO, also named transfusion-associated congestive heart headache, anxiety, rigors (shivering) as well as nausea and
failure, is probably underreported. The incidence rate of vomiting [220]. These symptoms usually appear at the end or
TACO collected by the SHOT system is 1/34,091 transfu- just after the end of transfusion. FNHTR is thought to be
sion, but Popovsky believes that the real incidence rate can caused primarily by two mechanisms involving white blood
be up to 1 % [220], especially after massive transfusions. cells. Firstly, FNHTR may occur when HLA antibodies presThe incidence rate of TACO in PICU is unknown, but in ent in a recipient react with donor white blood cells present
2010, TACO was the most common transfusion-related death in a RBC or platelet component. This leads to complement
in UK. According to the British Haemovigilance System activation and cytokine release, which results in the typical
(SHOT), a TACO is present if at least four of the five follow- symptoms of a FNHTR. Alternately (and likely more coming criteria are met within 6 h after a transfusion: (1) acute monly, at least in the case of platelet transfusions) cytokines
respiratory distress; (2) tachycardia; (3) increased blood are released from white blood cells during the storage of
pressure; (4) acute or worsening pulmonary edema; (5) evi- blood components; when transfused, these cytokines can
dence of positive fluid balance reports>. All patients with cardiac disease or chronic anemia with fever episodes decreased from 24.7 % prior to the intro(Hb < 5 g/dL) are at risk, including newborns. Circulatory duction of the pre-storage leukoreduction program to 22.5 %
overload can be prevented to some extent by slowing the rate following its implementation in Canada (OR 0.88; 95 % CI
of transfusion (to less than 1 mL/kg/h) in patients at risk. 0.82–0.95; p = 0.001) [242]. It may be useful to use washed
Other modalities include pre-emptive diuretics and splitting blood products for patients with a history of repeated and
components into smaller aliquots. Treatment consists in ces- severe FNHTR to leukocyte-reduced blood products.
sation of the transfusion, attention to fluid balance, use of Acetaminophen can be used to minimize fever, but premedication with acetaminophen, diphenhydramine or steroids is
diuretics if necessary and supportive ventilatory measures.
not helpful [243, 244].
Hypotensive Reaction
Hypotension following transfusion of a blood product is rare Acute Hemolytic Transfusion Reactions
(1/102,273 transfusions in Canada [207]), but case reports Acute hemolytic transfusion reactions are characterized by
have been published describing it both in adult and pediatric hemoglobinuria and/or hemoglobinemia (blood level of free
patients [238]. In most instances, these reactions seem to be Hb above normal range) with at least one of the following

276

symptoms and signs: de novo fever, dyspnea, hypotension
and/or tachycardia, anxiety/agitation, pain [220]. Acute
hemolytic reactions are rare (1/26,914 according to
MacDonald et al. [207]), but may be fatal. The destruction of
RBCs in the recipient is attributed to immunological incompatibility (donor RBC antigens reacting with recipient antibodies). Acute hemolytic reactions are usually caused by the
transfusion of an incompatible blood product, an adverse
event that is attributable to error in 86 % of cases. Acute
hemolysis due to ABO incompatibility is the leading cause
of severe reaction to RBC transfusion (1/108,968 RBC transfusions) [207]; however, other erythrocyte antigens can be
involved (D/d, C/c, E/e, Kell, etc.). Hemolysis is associated
with hemoglobinuria and acute anemia. Fever is also frequent, as well as shivering, discomfort and general pain. In
severe cases, hypotension, shock, renal insufficiency and
DIC can be observed. A mortality rate as high as 10 % is
reported [197]. In order to prevent such hemolytic reactions,
correct labeling of the blood sample for pre-transfusion testing is essential and, at the time of transfusion, compatibility
between donor and recipient including ABO and Rh groups,
the identification number of the unit as well as the identity of
the recipient (name and hospital chart number) must be
meticulously verified and routinely double-checked at the
patient’s bedside.

M. Tucci et al.

mild reactions. Fever is usually not observed, but a rash is
possible. Severe allergic reaction may be life-threatening
[197]. It is advisable to administer antihistamines prior to
transfusing patients who have presented repeated minor

allergic reactions to blood products; the use of corticosteroids as well as using washed packed RBC units or platelet
concentrates may also be considered particularly for severe
or repeated reactions that do not respond to premedication
with antihistamines. Patients with an IgA deficiency and
anti-IgA should receive blood from donors with that same
deficit or, in the case of cellular blood components, products
that have been thoroughly washed. White blood cell reduction does not prevent allergic reactions.

Infections
All blood product administration involves a potential for
transmission of infections. Bacterial contamination of blood
products is the cause of 10 % of deaths attributable to transfusions. The risk of bacterial contamination is higher for
platelets (1/31,189 units) than for RBC units (1/65,381 units)
[207], as platelets are stored at 22 °C while RBCs are stored
at 4 °C. Many preventive techniques have been implemented
in the last years in order to decrease the risk of bacterial
infections caused by platelet transfusions, which have significantly improved the safety of platelets transfusions. For
example, the incidence in the Province of Quebec of probable and definite transfusion-transmitted bacterial infections
Non-immunologic Hemolysis
Non-immunologic hemolysis can be caused by mechanical associated with whole blood-derived platelets decreased
trauma to RBCs (transfusion through a very small needle from 1 in 2,655 in 2000 to 1 in 58,123 five-unit pools in 2008
with high pressure), use of a cell-saver device or mechanical (p < 0.001) [245]. It is estimated that transfusion-related sepwarmer (excessive warming), incorrect storage (e.g. if tem- sis occurs in 15–25 % of patients who receive contaminated
perature goes below 0 °C), injection using lines that contain platelet concentrates [211]. Potential sources of contamination include unrecognized bacteremia in the donor due to
a hypotonic solution and bacterial contamination.
Yersinia enterolytica or Salmonella gastroenteritis,
Staphylococcus aureus infection caused by dental manipulaAllergic Reactions
Allergic reactions related to type I hypersensitivity reactions tion, contamination of donated blood by normal skin flora
can occur when allergens from the donor react with antibod- during collection and infection occurring due to manipulaies from the receiver. Such reactions are usually minor (urti- tion of blood products. The most common germs are: Gram
caria: 1/100 RBC units [163],) but may be severe negative bacteria like Klebsiella pneumoniae, Serratia marc(anaphylaxis: 1/20,000 RBC units) [163]. As reported by escens and Pseudomonas species, and Gram positive like
SHOT (2010 Annual Report

reports>), “anaphylactic reactions… occur most frequently Bacillus cereus. The reaction usually occurs during or within
during the first 15 min of a transfusion (mean time to onset a few hours after transfusion and can cause milder symptoms
26 min in cases reported in 2010)”, but the risk exists such as fever and shivering as well as more severe complicathroughout the whole transfusion episode. At least one of the tions such as septic shock. The risk of bacteremia is more
following signs/symptoms is present in severe cases: cardiac important with prolonged storage time. When a bacterial
arrest, generalized allergic reaction or anaphylactic reaction, contamination is suspected, the transfusion must be stopped
angioedema (facial and/or laryngeal), upper airway obstruc- immediately, wide spectrum antibiotics must be given (third
tion, dyspnea, wheezing, hypotension, shock, precordial generation cephalosporin or beta-lactam in combination with
pain, chest tightness, cardiac arrhythmia or loss of con- aminoglycoside) and supportive treatment administered. The
sciousness [220]. The risk for severe allergic reactions is blood bank must be informed immediately, as other blood
greater in patients with IgA antibodies associated with IgA products from the same donor may need to be withdrawn.
deficiency. Severe reactions usually occur more rapidly than Culture of the blood product itself is indicated. Several blood


19  Transfusion Medicine

277

suppliers now perform bacterial detection studies on platelet
concentrates prior to their release into hospital inventories,
but even this technique does not detect all contaminated
units.

kg/min and of whole blood or plasma at a rate greater than
1 mL/kg/min [250, 251]. Citrate intoxication can cause
severe hypocalcemia [252]. Callum et al. [205] recommended the following strategy in order to avoid complications related to massive transfusion: monitor core temperature
Acute Leukocytosis
and prevent hypothermia using a blood warmer for all intraAcute leukocytosis is rare after transfusion of leukocyte-­ venous fluids and blood components; monitor the coagulareduced RBC units, but may occur after the transfusion of tion profile and transfuse platelets, plasma or cryoprecipitate
non filtered units [86]. White blood cells can reach values as to maintain a platelet count >50,000/mm3, an INR < 1.5–2.0
high as 40 × 109/L, but return to normal within 24 h [86].
and fibrinogen level over 0.1 g/dL; monitor hyperkalemia,

acidosis and hypocalcemia, and give CaCl2 if necessary.

Acute Complications of Massive Transfusion
Massive transfusion is defined as the administration of more
than one blood volume of blood products within a 24 h
period, or more than 50 % of the circulating blood volume in
3 h or less, or ten RBC units in adults [199]. Serious acute
complications of massive transfusion include fluid overload,
hypothermia, coagulopathy and thrombocytopenia, acidosis,
citrate intoxication, hyperkalemia and hypocalcemia [246].

Hypothermia
The massive transfusion of blood products can cause hypothermia, which can lead to problems like tissue hypoxia,
arrhythmias, coagulation disorders (increased PT and PTT,
platelet dysfunction), increased blood viscosity, high blood
lactate level, hyperkalemia and decreased metabolism of
drugs. Mortality is higher if the body temperature drops
below 34 °C [247]. Treatment and prevention of hypothermia involve warming blood products as well as the patient
(blanket, heating lamp, etc.).
Coagulopathy
The coagulopathy and thrombocytopenia observed after
massive transfusion of RBC units is attributed to hemodilution, hypothermia, administration of blood products with a
prolonged length of storage and DIC [248]. Transfusion-­
related coagulopathy can be diagnosed if at least one of the
following criteria is observed during or shortly after a massive transfusion: INR (international normalized ratio) >2.0;
activated partial thromboplastin time (aPTT) >60 s; positive
assay for fibrin-split products; D-dimers >0.5 mg/mL [220].
It is frequently recommended to give plasma and platelets if
a RBC volume corresponding to 1–1.5 times the circulating
blood volume is administered within a short period of time.

Citrate Intoxication
Citrate can cause early onset acidemia, though metabolic
alkalosis can also develop due to the liver metabolizing
citrate [249]. Citrate intoxication occurs if the metabolic
capacity of the liver is overwhelmed, which can occur with
administration of packed RBCs at a rate greater than 3 mL/

Hyperkalemia
Hyperkalemia is a potential complication with all RBC
transfusions, especially if the transfusion is given rapidly.
Potassium is released in the supernatant by RBC leak or
lysis. Its level increases linearly and is approximately equal
to the number of days of storage [253]. Potassium levels
have been measured in CPDA-1 and SAGM: it increases
from 5.1 to 78.5 mmol/L (1st–35th day) in the former, from
2.1 to 45 mmol/L (1st–42nd day) in the latter [253].
Irradiation further increases the potassium concentration in
units stored following irradiation [254]. Monitoring of potassium levels in transfusion recipients is essential, and it is
advisable to administer packed RBCs at a rate no greater
than 0.3 mL/kg/min whenever possible. Notwithstanding
these concerns, the frequency of hyperkalemia caused by
RBC transfusion is low. Parshuram et al. [254] have shown
that the transfusion of 11 mL/kg of packed RBC units to
critically ill children increases the potassium blood level
from 3.85 ± 0.55 to 3.94 ± 0.62 mmol/L, a difference that is
not clinically, nor statistically significant.

Late Onset Reactions and Complications
Late reactions to transfusion occur days, weeks or even years
after the transfusion. Serious late-onset non-infectious complications of blood transfusions include hemolysis (delayed

hemolytic transfusion reaction), transfusion-transmitted
infections, post-transfusion purpura, allo-immune thrombocytopenia, graft versus host disease, and possibly (though
controversial) TRIM (see above).

Delayed Hemolytic Reactions
In 2006, the incidence rate of delayed hemolytic reactions
was one per 255,682 transfusions in Canada [207]. Delayed
hemolytic reactions are caused by antibodies in the recipient
that are not detected during pre-transfusion compatibility
testing and that developed either because of prior RBC transfusions or because of exposure to RBCs of fetal origin. The
most frequently involved antibodies are: E, Jk a, c, Fya, K
[255]. The hemolytic reaction usually begins 3–14 days after


278

transfusion. Most cases are mild and resolve spontaneously,
but severe cases can occur, especially in sickle cell patients
(hyperhemolysis). There is no specific treatment. Erythrocyte
alloimmunization following transfusion can occur in 1–8 %
of recipients and is a particular concern in young girls who
may then be at risk for hemolytic disease of the fetus/newborn in future pregnancies [163].

Post-Transfusion Purpura (PTP)
PTP is rare, but can be severe. It manifests itself by a low
platelet count (below 10 × 109/L) any time between 1 and
24 days after transfusion in patients sensitized to platelet
antigens by prior transfusion or pregnancy [197]. The pathogenesis is unclear and presumably is related to the presence
of platelet-specific antibodies in the recipient following previous exposure to human platelets. These antibodies destroy
both transfused platelets and the recipient’s own platelets.

Severe hemorrhage can occur in the gut, urinary tract and/or
brain. The thrombocytopenia is refractory to platelet transfusion and the mortality rate is reported to be as high as 8 %
[256]. Giving platelet concentrates that are free of the implicated platelet antibodies to susceptible patients can prevent
this type of reaction. The thrombocytopenia appears suddenly, but it is usually self-limiting. Steroids, plasmapheresis
and immunoglobulins may be required in severe cases. The
acute onset of severe thrombocytopenia following transfusion can also occur when a plasma-containing component
from a donor with anti-platelet antibodies is administered to
a recipient possessing the corresponding platelet antigen.
Infections
Nowadays, non-infectious serious hazards of transfusion
(NiSHOTs) are more frequent and more challenging to practitioners than transfusion-transmitted infectious diseases
[58]. This does not mean that there is no risk. There will
always be some residual risk of infections, attributable to the
“window period” (time from the beginning of an infection to
the time when tests can detect the infection) and to false negative results. Table 19.3 lists the most frequent or most
important infections attributable to transfusions. Although
transfusion transmitted hepatitis B virus (HBV), hepatitis C
virus (HVC) and human immuno-deficiency virus (HIV)
have become exceedingly rare, the risk of transfusion transmitted infectious diseases including the risk of bacterial contamination, cytomegalovirus (CMV) transmission and
infection with emerging infectious disease agents and with
viruses for which testing is not currently performed (e.g.
human herpesvirus-8) [257] continues to be a major concern
[258]. Transmission of insect-borne zoonosis is also a well-­
recognized problem (for example: West Nile virus [213],
malaria [259], babesiosis [260], Bartonella Quintana [261])
A few cases of prion (agent causing variant Creutzfeld-Jacob
disease or vCJD) transmission by a transfusion have been

M. Tucci et al.

reported [212]. SD plasma has a reduced risk of infection
related to enveloped viral pathogens, but the risk for non-­
enveloped viruses is not affected.

Transfusion Associated Graft Versus Host Disease
(TA-GvHD)
TA-GvHD is a rare adverse event that can be extremely
severe [214, 262]. The “Serious hazard of transfusion
(SHOT) initiative” run in United Kingdom reported that 8
out of 22 deaths (36 %) attributed to a transfusion were
caused by a TA-GvHD [263]. TA-GvHD has occurred in two
settings. The first clinical setting in which TA-GvHD occurs
is severely immunocompromised patients (such as those
with congenital immune deficiency syndromes or cancer
patients receiving chemotherapy) or preterm infants with
immature immune systems unable to reject donor T lymphocytes found in cellular blood components [264]. Hence the
donor T lymphocytes are able to engraft, proliferate, and
then attack recipient tissues. An ICU group at particular risk
is DiGeorge patients undergoing cardiovascular surgery for
congenital cardiac anomalies associated with this syndrome.
Surprisingly HIV infected patients are not at risk for
TA-GvHD. The second clinical setting in which TA-GvHD
occurs is the setting in which donor lymphocytes are able to
engraft because they are not recognized as foreign by a non-­
immunosuppressed receiver. This occurs when the donor is
HLA homozygous for one of the HLA haplotypes present in
an HLA heterozygous recipient. This situation can occur in a
population with relative HLA homogeneity (e.g. the
Japanese) or in the setting of directed donations from biologic relatives or if HLA-matched platelets are given to treat
a patient with immune refractoriness to unmatched platelets

[2, 264]. Symptoms usually appear 8–28 days after transfusion and include fever, skin rash, diarrhea and hepatic dysfunction. A severe pancytopenia can be caused by bone
marrow dysfunction. TA-GvHD is fatal in 90 % of patients if
untreated, a fatality rate that is significantly higher than with
GvHD related to bone marrow transplantation [84].
Lymphocyte multiplication can be blocked by irradiation,
which dramatically reduces and probably eliminates the risk
of contracting TA-GvHD. Leukoreduction of cellular components is not sufficient to prevent TA-GvHD.

 on-specific Treatment of Transfusion
N
Reactions
When a transfusion reaction is suspected, the following
actions must be undertaken immediately:
• Stop the transfusion immediately.
• Check if the patient received the correct unit.
• Maintain an intravenous access with NaCl 0.9 %.
• Insure patient stability.


19  Transfusion Medicine

• Re-check identification of patient and blood product.
• Report in detail the clinical data of the event in the hospital chart.
• Monitor the patient for at least a few hours.
• Collect blood cultures from the patient if bacteremia is
suspected,
• Measure antibodies, antigens, free Hb or other markers of
metabolic disturbance (acidosis, hyperkalemia, hypocalcemia, etc.) if appropriate.
Some attention must also be paid to the transfused unit:
• Look at the unit and describe your observation in the

patient’s hospital chart.
• Return the unit that was being transfused, the filter and
the tubing being used, and the remaining blood product to
the blood bank.
All possible transfusion reactions must be immediately
reported to the appropriate blood agency, which is the blood
blank in many hospitals.

References
1.Bateman ST, Lacroix J, Boven K, et al. Anemia, blood loss and
blood transfusion in North American children in the intensive care
unit. Am J Respir Crit Care Med. 2008;178:26–33.
2. Gibson BE, Todd A, Roberts I, et al. Transfusion guidelines for
neonates and older children. Br J Haematol. 2004;124:433–53.
3. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant
human erythropoietin in critically ill patients. JAMA. 2002;288:
2827–35.
4.Hébert PC, Lacroix J. Décision de transfusion érythrocytaire en
réanimation. Réanimation. 2003;12:615–22.
5.Rasanen J. Supply-dependent oxygen consumption and mixed
venous oxyhemoglobin saturation during isovolemic hemodilution
in pigs. Chest. 1992;101:1121–4.
6.Van der Linden P, Schmartz D, De Groote F, et al. Critical haemoglobin concentration in anaesthetized dogs: comparison of two
plasma substitutes. Br J Anaesth. 1998;81:556–62.
7.Shander A. Anemia in the critically ill. Crit Care Clin. 2004;20:
159–78.
8. Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet.
1996;348:1055–60.
9. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline
blood transfusion. Transfusion. 2002;42:812–8.

10. English M, Ahmed M, Ngando C, Berkley J, Ross A. Blood transfusion for severe anaemia in children in a Kenyan hospital. Lancet.
2002;359:494–5.
11. Lackritz EM, Campbell CC, Ruebush TK, et al. Effect of blood
transfusion on survival among children in a Kenyan hospital.
Lancet. 1992;340:524–8.
12. Lackritz EM, Hightower AW, Zucker JR, et al. Longitudinal evaluation of severely anemic children in Kenya: the effect of transfusion
on mortality and hematologic recovery. AIDS. 1997;11:1487–94.
13.Hébert PC, Van der Linden P, Biro G, Hu LQ. Physiologic aspects
of anemia. Crit Care Clin. 2004;20:187–212.
14.Morisaki H, Sibbald WJ. Tissue oxygen delivery and the microcirculation. Crit Care Clin. 2004;20:213–23.
15. Doctor A, Stamler JS. Nitric oxide transport in blood: a third gas in
the respiratory cycle. Compr Physiol. 2011;1:611–38.

279
16.Rogers S, Doctor A. Vasoregulation by red blood cells. In: Spinella
PC, Nakagawa TA, editors. Current concepts in pediatric critical
care. Des Plaines: Society of Critical Care Medicine; 2011. p.
21–39.
17. Hébert PC, Qun Hu L, Biro GP. Review of physiologic mechanisms
in response to anemia. Can Med Assoc J. 1997;156 Suppl 11:
S27–40.
18. Hameed SM, Aird WC, Cohn SM. Oxygen delivery. Crit Care Med.
2003;31:S658–67.
19.Alkalay AL, Galvis S, Ferry DA, Simmons CF, Krueger RCJ.
Hemodynamic changes in anemic premature infants: are we allowing the hematocrits to fall too low? Pediatrics. 2003;112:838–45.
20.Duke TD, Butt W, South M. Predictors of mortality and multiple
organ failure in children with sepsis. Intensive Care Med. 1997;23:
684–92.
21. Mercier JC, Beaufils F, Hartmann JF, Azema D. Hemodynamic patterns of meningococcal shock in children. Crit Care Med. 1988;16:
27–33.

22.Doughty LA, Kaplan SS, Carcillo JA. Inflammatory cytokine and
nitric oxide responses in pediatric sepsis and organ failure. Crit
Care Med. 1996;24:1137–43.
23. Hinshaw LB. Sepsis/septic shock, participation of the microcirculation: an abbreviated review. Crit Care Med. 1996;24:1072–8.
24.Lacroix J, Pineault M, Rozé JC. Alimentations entérale et parentérale. In: Lacroix J, Gauthier M, Beaufils F, editors. Urgences et
soins intensifs pédiatriques. Montréal et Paris: Les Presses de
l’Université de Montréal et Doin; 1994. p. 103–24.
25. Leteurtre S, Martinot A, Duhamel A, et al. Validation of the pediatric logistic organ dysfunction (PELOD) score. A prospective multicenter study. Lancet. 2003;362:192–7.
26.Slater A, Shann F, Pearson G, Paediatric Index of Mortality (PIM)
Study Group. PIM2: a revised version of the Paediatric Index of
Mortality. Intensive Care Med. 2003;29:278–85.
27.Desmet L, Lacroix J. Transfusion in pediatrics. Crit Care Clin.
2004;20:299–311.
28. Lacroix J, Toledano B. Erythropoietin for critically ill children.
Pediatr Crit Care Med. 2003;4:123–4.
29. Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M. Epidemiology
of sepsis and multiple organ dysfunction syndrome in children.
Chest. 1996;109:1033–7.
30.Corwin HL, Krantz SB. Anemia of the critically ill: “Acute” anemia of chronic disease. Crit Care Med. 2000;28:3098–9.
31.Hobisch-Hagen P, Wiedermann F, Mayr A, et al. Blunted erythropoietic response to anemia in multiply traumatized patients. Crit
Care Med. 2001;29:743–7.
32.Scharte M, Fink MP. Red blood cell physiology in critical illness.
Crit Care Med. 2003;31:S651–7.
33. Cohn SM. Blood substitutes. New Horiz. 1999;7:54–60.
34. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21:327–48.
35. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA. 1993;269:3024–9.
36.Soifer SJ. Pulmonary hypertension: physiologic or pathologic disease? Crit Care Med. 1993;21:S371–4.
37.Messmer K, Sunder-Plassmann L, Klovekorn WP, Holper K.

Circulatory significance of hemodilution: rheological changes and

limitations. Adv Microcirc. 1972;4:1–77.
38.Weg JG. Oxygen transport in adult respiratory distress syndrome
and other acute circulatory problems: relationship of oxygen delivery and oxygen consumption. Crit Care Med. 1991;19:650–7.
39. Tissot JD, Rubin O, Canellini G. Analysis and clinical relevance of
microparticles from red blood cells. Curr Opin Hematol. 2010;17:
571–7.
40.Jy W, Ricci M, Shariatmadar S, Gomez-Marin O, Horstman LH,
Ahn YS. Microparticles in stored red blood cells as potential mediators of transfusion complications. Transfusion. 2011;51:886–93.


280
41.Spinella PC, Sparrow RL, Hess JR, Norris PJ. Properties of stored
red blood cells: understanding immune and vascular reactivity.
Transfusion. 2011;51:894–900.
42. Stack G, Baril L, Napychank P, Snyder EL. Cytokine generation in
stored, white cell-reduced, and bacterially contaminated units of
red cells. Transfusion. 1995;35:199–203.
43. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA,
Lym GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168:2377–81.
44.Spinella PC, Carroll CL, Staff I, et al. Duration of red blood cell
storage is associated with increased incidence of deep vein thrombosis and in-hospital mortality in patients with traumatic injuries.
Crit Care Med. 2009;13:R151.
45.Grimshaw K, Sahler J, Spinelli SL, Phipps RP, Blumberg N. New
frontiers in transfusion biology: identification and significance of
mediators of morbidity and mortality in stored red blood cells.
Transfusion. 2011;51:874–80.
46.Jy W, Horstman LL, Ahn YS. Microparticle size and its relation to
composition, functional activity, and clinical significance. Semin
Thromb Hemost. 2010;36:876–80.
47. Rubin O, Crettaz D, Tissot JD, Lion N. Microparticles in stored red

blood cells: submicron clotting bombs? Blood Transfus. 2010;8
Suppl 3:s31–8.
48.Welch HG, Meehan KR, Goodnough LT. Prudent strategies for
elective red blood cell transfusion. Ann Intern Med. 1992;116:
393–402.
49.Heaton A, Keegan T, Holme S. In vivo regeneration of red cell
2,3-diphosphoglycerate following transfusion of DPG-depleted
AS-1, AS-3 and CPDA-1 red cells. Br J Haematol. 1989;71:131–6.
50.Dzik WH. The air we breathe: three vital respiratory gases and the
red blood cell: oxygen, nitric oxide, and carbon dioxide.
Transfusion. 2011;51:676–85.
51.Pagnier J, Marden M, Poyart C. Le point sur les transporteurs
d’oxygène à base d’hémoglobine. Méd Sci. 1996;12:1342–50.
52.Kim-Shapiro DB, Lee J, Gladwin MT. Storage lesion: role of red
blood cell breakdown. Transfusion. 2011;51:844–51.
53.Nishiyama T, Hanaoka K. Hemolysis in stored red blood cell concentrates: modulation by haptoglobin or ulinastatin, a protease
inhibitor. Crit Care Med. 2001;29:1979–82.
54.Hess JR, Sparrow RL, van der Meer PF, Acker JP, Cardigan RA,
Devine DV. Red blood cell hemolysis during blood bank storage:
using national quality management data to answer basic scientific
questions. Transfusion. 2009;49:2599–603.
55.Reynolds JD, Hess DT, Stamler JS. The transfusion problem: role
of aberrant S-nitrosylation. Transfusion. 2011;51:852–8.
56. Bennett-Guerrero E, Veldman TH, Doctor A, et al. Evolution of
adverse changes in stored RBCs. Proc Natl Acad Sci U S A.
2007;104:17063–8.
57.Doctor A, Platt R, Sheram ML, et al. Hemoglobin conformation
couples erythrocyte S-nitrosothiol content to O2 gradients. Proc
Natl Acad Sci U S A. 2005;102:5709–14.
58.Roback JD, Neuman RB, Quyyumi A, Sutliff R. Insufficient nitric

oxide bioavailability: a hypothesis to explain adverse effects of red
blood cell transfusion. Transfusion. 2011;51:859–66.
59. Mink RB, Pollack MM. Effect of blood transfusion on oxygen consumption in pediatric septic shock. Crit Care Med. 1990;18:1087–91.
60.Seear M, Wensley D, MacNab A. Oxygen consumption-oxygen
delivery relationship in children. J Pediatr. 1993;123:208–14.
61.Beekman RH, Tuuri DT. Acute hemodynamic effects of increasing
hemoglobin concentration in children with a right to left ventricular
shunt and relative anemia. J Am Coll Cardiol. 1985;5:357–62.
62.Miletic VD, Popovic O. Complement activation in stored platelet
concentrates. Transfusion. 1993;33:150–4.
63. Fransen E, Maessen J, Dentener M, Senden N, Buurman W. Impact
of blood transfusions on inflammatory mediator release in patients
undergoing cardiac surgery. Chest. 1999;116:1233–9.

M. Tucci et al.
64. Knight JA, Voorhees RP, Martin L, Anstall H. Lipid peroxidation in
stored red cells. Transfusion. 1992;32:354–7.
65.Hayashi Y, Sawa Y, Nishimura M, et al. Clinical evaluation of leukocyte-depleted blood cardioplegia for pediatric open heart operation. Ann Thorac Surg. 2000;69:1914–9.
66. Smith KJ, Sierra ER, Nelson EJ. Histamine, IL-1ß and IL-8 increase
in packed RBCs stored for 42 days but not in RBCs leukodepleted
pre-storage. Transfusion. 1993;33:53S.
67.Voelkel NF. Hidden inflammatory potential of the red blood cell.
Crit Care Med. 2000;28:2149–50.
68. Marshall JC. A scoring system for multiple organ dysfunction syndrome. In: Vincent JL, Reinhart K, Eyrich K, Sprung C, editors.
Sepsis: current perspectives in pathophysiology and therapy. Berlin:
Springer; 1994. p. 38–49.
69.Marshall JC, Sweeney D. Microbial infection and the septic

response in critical surgical illness. Arch Surg. 1990;125:17–23.
70.Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical

care. N Engl J Med. 1999;340:409–17.
71. Nichols RL, Smith JW, Klein DB, et al. Risk of infection after penetrating abdominal trauma. N Engl J Med. 1984;311:1065–70.
72.Keown PA, Descamps B. Improved renal allograft survival after
blood transfusion: a nonspecific, erythrocyte-mediated immunoregulatory process? Lancet. 1979;1:20–2.
73. Kaplan J, Sarnaik S, Gitlin J, Lusher J. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of
repeated blood transfusions. Blood. 1984;64:308–10.
74.Kessler CM, Schulof RS, Goldstein AL, et al. Abnormal

T-lymphocyte subpopulations associated with transfusions of
blood-derived products. Lancet. 1983;1:991–2.
75. Tartter PI, Quintero S, Barron DM. Perioperative transfusions associated with colorectal cancer surgery: clinical judgment versus the
hematocrit. World J Surg. 1986;10:516–21.
76.Fielding LP. Red for danger: blood transfusion and colorectal cancer. Br Med J. 1985;291:841–2.
77.Yang H, Weaver AS, Gifford RRM. Transfusion effect still present
with quadruple immunosuppression in recipients of renal transplants. Transplant Proc. 1991;23:1247.
78. Katz MR, Barnhart GR, Goldman MH, et al. Pretransplant transfusions in cardiac allograft recipients. Transplantation. 1987;43:499.
79.Kerman RH, van Buren CT, Lewis RM, Frazier OH, Cooley D,
Kahan BD. The impact of HLA-A, B, and DR blood transfusions
and immune responder status on cardiac allograft recipients treated
with cyclosporin. Transplantation. 1988;45:333.
80. Opelz G, Sengar DPS, Mickey MR, Terasaki PI. Effect of blood transfusion on subsequent kidney transplants. Transplant Proc. 1973;5:253.
81. Singal DP, Ludwin D, Blajchman MA. Blood transfusion and renal
transplantation. Br J Haematol. 1985;61:595.
82.Singal DP. Immunological effects of blood transfusion. In: Hamblin
TJ, editor. Immunotherapy of disease. London: Kluwer; 1989. p. 167.
83.Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care
Med. 1996;24:1125–8.
84. Roseff SD, Luban NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion. 2002;42:1398–413.
85. Sharma AD, Sreeram G, Erb T, Grocott HP, Slaughter TF.
Leukocyte-reduced blood transfusions: perioperative indications,

adverse effects, and cost analysis. Anesth Analg. 2000;90:1315–23.
86.Izbicki G, Rudensky B, Na’amad M, Huerta M, Hersch M.

Transfusion-related leukocytosis in critically ill patients. Crit Care
Med. 2004;32:439–42.
87.Wadhwa M, Seghatchian MJ, Dilger P, et al. Cytokines in WBC-­
reduced apheresis PCs during storage: a comparison of two WBC-­
reduction methods. Transfusion. 2000;40:1118–26.
88. Weisbach V, Wanke C, Zingsem J, Zimmermann R, Eckstein R.
Cytokine generation in whole blood leukocyte-depleted and temporarily warmmed red blood cell concentrates. Vox Sang. 1999;76:100–6.


19  Transfusion Medicine
89.Sparrow RL, Patton KA. Supernatant from stored red blood cell
primes inflammatory cells: influence of prestorage white cell
reduction. Transfusion. 2004;44:722–30.
90.Spinella PC, Dressler A, Tucci M, et al. Survey of transfusion
policies at US and Canadian children’s hospitals in 2008 and
2009. Transfusion. 2010;50:2328–35.
91.Houbiers JG, van de Velde CJ, van de Watering LM, et al.
Transfusion of red cells is associated with increased incidence of
bacterial infection after colorectal surgery: a prospective study.
Transfusion. 1997;37:126–34.
92.Heiss MM, Memple W, Jauch KW, et al. Beneficial effects of
autologous blood transfusion on infectious complications after
colorectal cancer surgery. Lancet. 1993;342:1328–33.
93.Mezrow CK, Bergstein I, Tartter PI. Postoperative infections following autologous and homologous blood transfusions. Transfusion.
1992;32:27–30.
94. Murphy P, Heal JM, Blumberg N. Infection or suspected infection
after hip replacement surgery with autologous or homologous

blood transfusions. Transfusion. 1991;31:212–7.
95.Murphy PJ, Connery C, Hicks GL, Blumberg N. Homologous
blood transfusion as a risk factor for postoperative infection after
coronary artery bypass graft operations. J Thorac Cardiovasc
Surg. 1992;104:1092–9.
96.Pinto V, Baldonedo R, Nicolas C, Barez A, Perez A, Aza
J. Relationship of transfusion and infectious complications after
gastric carcinoma operations. Transfusion. 1991;31:114–8.
97.Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative
infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg.
1992;79:513–6.
98.Taylor RW, Manganaro L, O’Brien J, Trottier SJ, Parkar N,
Veremakis C. Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit
Care Med. 2002;30:2249–54.
99. Vamvakas EC. Pneumonia as a complication of blood product
transfusion in the critically ill: transfusion-related immunomodulation (TRIM). Crit Care Med. 2006;34:S151–9.

100.
Bernard AC, Davenport DL, Chang PK, Vaughan TB,
Zwishcenberger JB. Intraoperative transfusion of 1 U to 2 U
packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J Am Coll Surg. 2009;208:931–9.
101.Karger R, Stangenberg K, Hinrichs F, Griss P, Kretschmer V.
Safety and efficacy of unmodified whole blood vs. buffy coat-­
depleted red cell concentrates in autologous transfusion of elective
orthopaedic surgery patients. Transfus Med. 2004;14:347–57.
102. Innerhofer P, Klingler A, Klimmer C, Fries D, Nussbaumer W. Risk
for postoperative infection after transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic
patients undergoing primary arthroplasty. Transfusion. 2005;45:
103–10.
103. Vamvakas EC. WBC-containing allogeneic blood transfusion and

mortality: a meta-analysis of randomized controlled trials. Transfusion.
2003;43:963–73.
104. Vamvakas EC. White blood cell-containing allogeneic blood
transfusion, postoperative infection and mortality: a meta-analysis
of observational ‘before-and-after’ studies. Vox Sang. 2004;86(2):
111–9.
105. Bosman GJ, Werre JM, Willekens FL, Novotný VM. Erythrocyte
ageing in vivo and in vitro: structural aspects and implications for
transfusion. Transfus Med. 2008;18:335–47.
106. Tinmouth A, Fergusson D, Chin-Yee I, Hebert PC. Clinical consequences of red cell storage in the critically ill. Transfusion.
2006;46:2014–27.
107.Lacroix J, Tucci M. Impact clinique de la durée d’entreposage des
globules rouges avant transfusion. Transf Clin Biol. 2011;18:97–105.

281
108.Gauvin F, Spinella PS, Lacroix J, et al. Association between
length of storage of transfused red blood cells and multiple organ
dysfunction syndrome in pediatric intensive care. Transfusion.
2010;50:1902–13.
109. Karam O, Tucci M, Bateman ST, et al. Association between length
of storage of red blood cell units and outcome of critically ill children. Crit Care. 2010;14:R57.
110. Weinberg JA, McGwin G, Marques MB, et al. Transfusions in the
less severely injured: does age of transfused blood affect outcomes? J Trauma. 2008;65:794–8.
111.Taylor RW, O’Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care
Med. 2006;34:2302–8.

112.Leal-Noval SR, Jara-López I, García-Garmendia JL, et al.
Influence of erythrocyte concentrate storage time on postsurgical
morbidity in cardiac surgery patients. Anesthesiology. 2003;98:
815–22.

113. Vamvakas EC, Carven JH. Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: effect of the length
of storage of transfused red cells. Transfusion. 1999;39:701–10.
114. Offner PJ, Moore EE, Biffl WL, Johnson JL, Silliman CC.
Increased rate of infection associated with transfusion of old
blood after severe injury. Arch Surg. 2002;137:711–6.
115.Yap CH, Lau L, Krishnaswamy M, Gaskell M, Yii M. Age of
transfused red cells and early outcomes after cardiac surgery. Ann
Thorac Surg. 2008;86:554–9.
116.McKenny M, Ryan T, Tate H, Graham B, Young VK, Dowd N.
Age of transfused blood is not associated with increased postoperative adverse outcome after cardiac surgery. Br J Anaesth. 2011;
106:643–9.
117.van der Wal J, van Heerde M, Markhorst DG, Kneyber MC.
Transfusion of leukocyte-depleted red blood cells is not a risk factor for nosocomial infections in critically ill children. Pediatr Crit
Care Med. 2011;12:519–24.
118.Purdy FR, Tweeddale MG, Merrick PM. Association of mortality
with age of blood transfused in septic ICU patients. Can J Anaesth.
1997;44:1256–61.
119.Weinberg JA, McGwin G, Vandromme MJ, et al. Duration of red
cell storage influences mortality after trauma. J Trauma. 2010;69:
1427–31.
120.Pettila V, Westbrook AJ, Nichol AD, et al. Age of red blood cells
and mortality in the critically ill. Crit Care. 2011;15:R116.
121. Murrell Z, Haukoos JS, Putnam B, Klein SR. The effect of older
blood on mortality, need for ICU care, and the length of ICU stay
after major trauma. Am Surg. 2005;71:781–5.
122.Weinberg JA, McGwin G, Griffin RL, et al. Age of transfused
blood: an independent predictor of mortality despite universal leukoreduction. J Trauma. 2008;65:279–82.
123. Edgren G, Kamper-Jørgensen M, Eloranta S, etal. Duration of red
blood cell storage and survival of transfused patients (CME).
Transfusion. 2010;50:1185–95.

124.Basran S, Frumento RJ, Cohen A, et al. The association between
duration of storage of transfused red blood cells and morbidity and
mortality after reoperative cardiac surgery. Anesth Analg. 2006;103:
15–20.
125. Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated
coronary artery bypass grafting. Crit Care Med. 2006;34:1608–16.
126. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229–39.
127. Robinson SD, Janssen C, Fretz EB, et al. Red blood cell storage
duration and mortality in patients undergoing percutaneous coronary intervention. Am Heart J. 2010;159:876–81.
128. Eikelboom JW, Cook RJ, Liu Y, Heddle NM. Duration of red cell
storage before transfusion and in-hospital mortality. Am Heart
J. 2010;159:737–43.


282
129. van de Watering L, Lorinser J, Versteegh M, Westendord R, Brand
A. Effects of storage time of red blood cell transfusion on the
prognosis of coronary artery bypass graft patients. Transfusion.
2006;46:1712–8.
130. Deeks JJ, Dinnes J, D’Amico R, et al. Evaluating non-randomised
intervention studies. Health Technol Assess. 2003;7(iii–x):1–173.
131.Middelburg RA, van de Watering LMG, van der Bom JG. Blood
transfusions: good or bad? Confounding by indication, an underestimated problem in clinical transfusion research. Transfusion.
2010;50:1881–3.
132. Lacroix J, Hébert PC, Fergusson D, et al. The age of blood evaluation (ABLE) randomized controlled trial: study design. Transfus
Med Rev. 2011;25:197–205.
133.Fergusson D, Hutton B, Hogan DL, et al. The age of red blood
cells in premature infants (ARIPI) randomized controlled trial:
study design. Transfus Med Rev. 2009;23:55–61.
134. Steiner ME, Assmann SF, Levy JH, et al. Addressing the question of

the effect of RBC storage on clinical outcomes: the Red Cell Storage
Duration Study (RECESS). Transf Apher Sci. 2010;43:107–16.
135. Glynn SA. The red blood cell storage lesion: a method to the madness. Transfusion. 2010;50:1164–9.
136.Laverdière C, Gauvin F, Hébert PC, et al. Survey of transfusion
practices in pediatric intensive care units. Pediatr Crit Care Med.
2002;3:335–40.
137. Nahum E, Ben-Ari J, Schonfeld T. Blood transfusion policy
among European pediatric intensive care physicians. J Intensive
Care Med. 2004;19:38–43.
138. Gauvin F, Chaïbou M, Leteurtre S, et al. Pratique de transfusion de
concentré globulaire en réanimation pédiatrique: une étude
descriptive prospective. Réanim Urgences. 2000;9:339–44.
139. Armano R, Gauvin F, Ducruet T, Hume H, Lacroix J. Determinants
of red blood cell transfusions in a pediatric critical care unit: a
prospective descriptive epidemiological study. Crit Care Med.
2005;33:2637–44.
140.Williams GD, Bratton SL, Ramamoorthy C. Factors associated
with blood loss and blood product transfusions: a multivariate
analysis in children after open-heart surgery. Anesth Analg.
1999;89:57–64.
141. Cannesson M, Desebbe O, Rosamel P, et al. Pleth variability index
to monitor the respiratory variations in the pulse oximeter plethysmographic waveform amplitude and predict fluid responsiveness
in the operating theatre. Br J Anaesth. 2008;101:200–6.
142. Tschirch E, Weber B, Koehne P, et al. Vascular endothelial growth
factor as marker for tissue hypoxia and transfusion need in anemic
infants: a prospective clinical study. Pediatrics. 2009;123:784–90.
143. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy
in the treatment of severe sepsis and septic shock. N Engl J Med.
2001;345:1368–77.
144. de Oliveira CF, de Oliveira DS, Gottschald AF, et al. ACCM/PALS

haemodynamic support guidelines for paediatric septic shock: an
outcomes comparison with and without monitoring central venous
oxygen saturation. Intensive Care Med. 2008;34:1065–75.
145.Lacroix J, Hébert PC, Hutchison JH, et al. Transfusion strategies
for patients in pediatric intensive care units. N Engl J Med.
2007;356:1609–19.
146.Karam O, Tucci M, Ducruet T, et al. Red blood cell transfusion
thresholds in pediatric septic patients. Pediatr Crit Care Med.
2011;12:512–8.
147.Rouette J, Trottier H, Ducruet T, et al. Red blood cell transfusion
threshold in post-surgical pediatric intensive care patients. A randomized clinical trial. Ann Surg. 2010;251:421–7.
148. Palmieri TL, Lee T, O’Mara MS, Greenhalgh DG. Effects of
restrictive blood transfusion policy on outcomes in children with
burn injury. J Burn Care Res. 2007;28:65–70.
149. Rivers EP. Fluid-management strategies in acute lung injury–liberal, conservative, or both? N Engl J Med. 2006;354:2598–600.

M. Tucci et al.
150. Hébert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold
safe in critically ill patients with cardiovascular diseases? Crit
Care Med. 2001;29:227–34.

151.Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L,
Angelini GD. Increased mortality, postoperative morbidity, and
cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116:2544–52.
152. Kwiatkowski JL, Manno CS. Blood transfusion support in pediatric cardiovascular surgery. Transfus Sci. 1999;21:63–72.
153. Bernière J, Hartmann JF, Meyer P, Sellamy F. Transfusion érythrocytaire en réanimation pédiatrique. Réanimation. 2003;12:592–602.
154.Harrington K, Farrell C, Poirier N, Ducruet T, Lacroix J. Survey
on red-cell transfusion practices after paediatric cardiac surgery.
Pediatr Crit Care Med. 2011;12:A82.
155. Willems A, Harrington K, Lacroix J, et al. Comparison of two red-­

cell transfusion strategies after pediatric cardiac surgery. Crit Care
Med. 2010;38:649–56.
156. Henling CE, Carmichael MJ, Keats AS, Cooley DA. Cardiac operation for congenital heart disease in children of Jehovah’s
Witnesses. J Thorac Cardiovasc Surg. 1985;89:914–20.
157.Kawaguchi A, Bergsland J, Subramanian S. Total bloodless open
heart surgery in the pediatric age group. Circulation. 1984;70:1–30.
158. Cholette JM, Rubenstein JS, Alfieris GM, Powers KS, Eaton M,
Lerner NB. Children with single ventricle physiology do not benefit from higher hemoglobin levels following cavopulmonary connection: results of a prospective, randomized controlled trial of a
restrictive v. liberal red cell transfusion strategy. Pediatr Crit Care
Med. 2011;12:39–45.
159.Valentine T, Bateman S. Identifying factors to minimize phlebotomy induced blood loss in the pediatric ICU. Pediatr Crit Care
Med. 2012;13:22–7.
160. Rickard CM, Couchman BA, Schmidt SJ, Dank A, Purdie DM. A
discard volume of twice the deadspace ensures clinically accurate
arterial blood gases and electrolytes and prevents unnecessary
blood loss. Crit Care Med. 2003;31:1654–8.
161. Fowler RA, Rizoli SB, Levin PD, Smith T. Blood conservation for
critically ill patients. Crit Care Clin. 2004;20:313–24.
162.Consensus conference. Perioperative red blood cell transfusion.
JAMA. 1988;260:2700–3.
163. Experts Working Group. Guidelines for red blood cell and plasma
transfusions for adults and children. Can Med Assoc J. 1997;156
Suppl 11:S1–24.
164. Hebert PC, Fergusson DA, Stather D, et al. Revisiting transfusion
practices in critically ill patients. Crit Care Med. 2005;33:7–12.
165.Lacroix J, Tucci M. RBC transfusion in the PICU: the right cutoff? In: Shanley TP, editor. Current concepts in pediatric critical
care course. Des Plaines: Society of Critical Care Medicine; 2004.
p. 119–35.
166.Reinhart K, Kuhn HJ, Hartog C, Bredle DL. Continuous central
venous and pulmonary artery oxygen saturation monitoring in the

critically ill. Intensive Care Med. 2004;30:1572–8.
167.Committee on Standards of the American Association of Blood
Banks. Standards for blood blanks and transfusion services. 18th
ed. Bethesda: American Association of Blood Banks; 1997.
168.Roback JD, Combs MR, Grossman BJ, Hillyer CD. Technical
manual. 16th ed. Bethesda: AABB; 2008.
169. Elizalde JI, Clemente J, Marin JL, et al. Early changes in hemoglobin and hematocrit levels after packed red cell transfusion in
patients with acute anemia. Transfusion. 1997;37:573–6.
170. Hume HA. Blood components: preparation, indications and administration. In: Lilleyman J, Hann I, Blanchette V, editors. Pediatric hematology. 2nd ed. London: Churchill Livingston; 1999. p. 709–39.

171.Robitaille N, Hume HA. Blood components and fractionated
plasma products: preparation, indications and administration. In:
Arceci RJ, Hann IM, Smith OP, editors. Pediatric hematology. 3rd
ed. Oxford: Blackwell Publishing; 2006. p. 693–723.